



Universiteit
Leiden

The Netherlands

High-dimensional imaging of the HPV-induced tumor microenvironment to improve clinical outcomes

Abdulrahman, Z.

Citation

Abdulrahman, Z. (2026, September 3). *High-dimensional imaging of the HPV-induced tumor microenvironment to improve clinical outcomes*. Retrieved from <https://hdl.handle.net/1887/4309067>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4309067>

Note: To cite this publication please use the final published version (if applicable).


Chapter 5

Single-cell spatial transcriptomics unravels cell states and ecosystems associated with clinical response to immunotherapy

Ziena Abdulrahman, Roderick C. Slieker, Daniel McGuire,
Marij J.P. Welters, Mariette I.E. van Poelgeest, Sjoerd H. van der Burg

Journal for ImmunoTherapy of Cancer 2025

Graphical abstract



Key findings

What is already known on this topic

The tumor microenvironment (TME) plays a critical role in determining responses to immunotherapy. Studies focused on predefined cell populations, have identified several cells associated with treatment outcomes but simultaneously underscored the difficulty to use them as reliable biomarkers.

What this study adds

This study confirms the significant heterogeneity in the cellular composition of vulvar high-grade squamous intraepithelial lesions (vHsIL), and demonstrates that in particular the differences in spatial organization of immune cell states is associated with clinical response to immunotherapy.

How this study might affect research, practice, or policy

These findings underscore the importance of spatially resolved single-cell analyses in understanding the TME and suggest that targeting immune-supportive ecosystems could optimize immunotherapeutic strategies across tumor types.

Abstract

Background

The tumor microenvironment (TME) is a complex and dynamic ecosystem that is known to influence responses to immunotherapy. We leveraged single-cell spatial transcriptomics to systematically dissect the intricate complexity of the TME, in particular the cellular heterogeneity and spatial interactions. Their collective impact on immunotherapy efficacy was studied in the context of a homogenous group of patients with vulvar high-grade squamous intraepithelial lesions (vHSIL) treated with an immunotherapeutic tumor-specific peptide vaccine.

Methods

We performed single-cell spatial transcriptomics on 20 pre-treatment vHSIL lesions, stratified by clinical response to immunotherapeutic vaccination into complete responders (CR), partial responders (PR) and non-responders (NR). Using a 1000-gene panel, we mapped over 274,000 single cells in situ, identifying 18 cell clusters and 99 distinct non-epithelial cell states. Findings were validated against public single-cell transcriptomic datasets to assess their broader relevance across tumor types.

Results

Profound heterogeneity within the TME was detected across the response groups. CR lesions exhibited a higher ratio of immune-supportive to immune-suppressive cells—a pattern mirrored in other solid tumors following neoadjuvant checkpoint blockade. Key immune populations enriched in CRs included CD4+CD161+ effector T cells and chemotactic CD4+ and CD8+ T cells. Conversely, PRs were characterized by increased proportions of T helper 2 cells and CCL18-expressing macrophages, which are associated with the recruitment of type 2 T cells and regulatory T cells. NRs displayed preferential infiltration with immunosuppressive fibroblasts. Distinct spatial immune ecosystems further defined response groups. Although a number of immune cells were detected in all patients, type 1 effector cells dominated interactions in CRs, type 2 cells were prominently interacting in PRs, while NRs lacked organized immune cell interactions.

Conclusion

This study underscores the dual importance of both cellular composition and spatial organization in steering clinical response to immunotherapy.

Introduction

Over the past decade, there has been a significant surge in T cell-based immunotherapeutic approaches for cancer treatment, including immune checkpoint blockade, adoptive cell therapy, and therapeutic vaccines.¹⁻³ While these strategies have achieved remarkable success, many patients either fail to respond or experience only transient benefits. This underscores a critical need to deepen our understanding of how patient-specific tumor characteristics influence therapeutic responses. Retrospective analyses, typically focused on predefined markers and cell populations, have identified several tumor microenvironment (TME) features associated with treatment outcomes.⁴⁻⁵ However, the intricate complexity of the TME, particularly the cellular heterogeneity and spatial interactions, remains insufficiently understood, as does their collective influence on immunotherapy efficacy. Deciphering the multifaceted ecosystem of the TME—comprising diverse tumor, immune, and stromal cell populations, their cellular states, and their spatial interactions—could provide valuable insights into its role in modulating responses to specific immunotherapeutic interventions.⁶⁻⁹ Such an understanding has the potential to guide the identification of novel therapeutic targets and optimize patient selection, thereby enhancing the efficacy of immunotherapy.

In two clinical trials, we observed complete regression (CR) or partial regression (PR) in approximately half of the patients with human papillomavirus type 16 (HPV16)-induced vulvar high-grade squamous intraepithelial lesions (vHSIL) following treatment with an immunotherapeutic tumor-specific peptide vaccine comprising HPV16 E6/E7-specific synthetic long peptides.¹⁰⁻¹¹ Importantly, vHSIL patients represent a relatively homogeneous cohort, devoid of confounding factors such as differences in gender¹², stage, oncogenic pathways¹³⁻¹⁵, or tumor location¹⁶. These factors, known to influence TME composition, often complicate studies investigating the relationship between the TME and treatment outcomes. Clinical responsiveness in these trials correlated with the magnitude of the vaccine-induced systemic T cell response¹¹⁻¹⁷ and with a pre-existing abundance of T cells and myeloid cells within the TME prior to vaccination¹⁸. This association highlights the importance of the baseline immune landscape in determining therapeutic success and provides a foundation for further exploration of how TME features shape immunotherapy outcomes.

In this study, we employed single-cell spatial transcriptomics to measure RNA expression at subcellular resolution in formalin-fixed, paraffin-embedded (FFPE) whole tissue samples.¹⁹ This approach combines the high-resolution analytical power of single-cell RNA sequencing with the spatial context provided by *in situ* imaging. Consequently, it enables the interrogation of cellular heterogeneity without relying on predefined marker sets^{19,20-23}, allowing for a comprehensive digital reconstruction of the cellular landscape within these lesions. Furthermore, this methodology facilitated an in-depth analysis of cellular states and spatial interactions within TME in relation to clinical responses to immunotherapy. Key findings from this analysis were validated using publicly available immunotherapy datasets, underscoring the robustness and translational relevance of the results.

Materials and methods

Patient samples

Pre-vaccination formalin-fixed paraffin-embedded (FFPE) biopsies of 20 women of ≥ 18 years old with histologically confirmed HPV16⁺ vHSIL were analyzed. These women participated in a phase I/II therapeutic HPV16 SLP vaccination trial with ISA101.^{10,11} The ISA101 vaccine was injected subcutaneously and consisted of 13 synthetic long overlapping peptides covering the entire amino acid sequence of HPV16 oncoproteins E6 and E7, emulsified with Montanide adjuvant. Clinical efficacy assessments in the trial were performed 3 and 12 months after the last vaccination. The patients were classified based on their best clinical response 12 months after vaccination without additional treatment into: complete responders (CR, n=6) when the lesion completely disappeared, partial responders (PR, n=7) when $\geq 50\%$ of the total lesion area had disappeared, and non-responders (NR, n=7) when $< 50\%$ of the lesion had disappeared. All patients gave written informed consent to participate in this immunotherapeutic trial. The study was conducted in accordance with the Declaration of Helsinki and approved by the national Central Committee on Research Involving Human Subjects (CCMO, NL21215.000.08) and the Leiden University Medical Center institutional ethical committee (P08.197).

Statistical analyses

Statistical data analyses were performed with GraphPad Prism 9.3.1 and with R 4.4.0, which were also used to create graphs to visualize the data. In R, *ggplot2* (v3.5.1) was used to produce plots. The median immune counts of the three

different response groups were compared using the non-parametric Kruskal Wallis test, and of two response groups by the non-parametric Mann-Whitney U test. Bonferroni corrected p-values were marked as statistically significant.

Single-cell spatial transcriptomics

The patient samples, all diagnosed with vHSIL by a specialized pathologist, were analyzed with the CosMx Spatial Molecular Imager (Nanostring), which allowed the visualization of 1000 RNA transcripts at a subcellular resolution *in situ* on FFPE pre-immunotherapy vHSIL tissue, using cyclic fluorescent *in situ* hybridization.¹⁹ This technique allowed both the discovery of new cell types in the tumor microenvironment of vHSIL, as well as the exploration of their spatial interactions. The majority of the patients' vHSIL biopsies could be completely covered with fields of view (FOVs) for spatial transcriptomic analysis. Cell segmentation was performed with CellPose, which has been shown to be one of the most reliable methods.²⁴

Semi-supervised cell type classification

Cell type classification was performed using the semi-supervised cell typing method InSituType.²⁵ An initial round of cell typing was run using an immunology based cell type reference profile provided as the default in the R software package, and allowing for 6 unsupervised clusters to characterize epithelial cell types. Subsequently, cells which were classified as an immune cell type were further refined by clustering smoothed averages of marker genes for the cell's nearest neighbors (<https://nanostring-biostats.github.io/CosMx-Analysis-Scratch-Space/posts/marker-gene-smoothing/>). Specifically, a set of 58 genes with known expression specificity in immune cells was pre-selected (**Supplemental Table 1**).

Let $\mathbf{X}_{\text{markers} \times \text{cells}}$ denote a total-count normalized expression matrix for cells classified as non-epithelial and their expression in the pre-selected marker gene set. Let $\mathbf{W}_{\text{cells} \times \text{cells}}$ denote a nearest neighbors matrix where each column indicates the nearest 50 neighbors of the corresponding cell in a uniform manifold approximation and projection (UMAP) space. Further each column was allowed to be standardized such that the sum of each column is 1. The 2D UMAP projection was created using pearson-residual normalized data²⁶ and default UMAP parameters implemented in Seurat software package.²⁷ Then the smoothed expression matrix $\mathbf{S}_{\text{markers} \times \text{cells}}$ takes the form $\mathbf{S} = \mathbf{X} \mathbf{W}$.

This smoothed expression matrix was clustered using k-means and cells were subsequently assigned to an immune cell type based on the expression characteristics of the corresponding k-means cluster.

Plausible gene filtering using a contamination ratio metric

For spatial transcriptomic data, one major challenge is dealing with the impact of cell segmentation uncertainty, where even minor errors can potentially confound or distort downstream analyses. For cell-type specific analyses, we develop a “contamination ratio metric” for pre-emptively excluding genes which may be likely to return spurious results due to imperfect cell segmentation.²⁸ Let $\bar{y}(t)_g$ denote the average expression of a particular gene g for a cell type t of interest. Further denote the average expression per cell of the gene in *neighboring cells* of other cell types by $\bar{y}(t')_g$. Then the ratio $\psi_g = \frac{\bar{y}(t')_g}{\bar{y}(t)_g}$ is a metric by which we quantify the susceptibility to confounding bias from segmentation error. Genes with $\psi_g > 1$ are higher expressed on average in neighboring cells of other cell types than that of cell type t . For cell type subclustering, we filtered the list of genes to be analyzed for a given cell type such that $\psi_g < 1$.

Subcluster identification

To further refine cell types into distinct cell states or subclusters, we first identified for each cell type, a list of genes that are plausibly expressed in that cell type to use for unsupervised subclustering. We defined this list of genes using the contamination ratio metric described above, selecting genes where the ratio metric $\psi_g < 1$. For a given cell type, this corresponds to subclustering using only genes with higher average expression within the cell type than in the spatially neighboring cells of other cell types. Unsupervised Louvain clustering was then performed among each cell type separately using only the filtered list of genes using Seurat.²⁷

Spatial co-localization of cell states

Multinomial logistic regression was used to characterize differential spatial colocalization of cell states between patient groups. First, we identified for each patient all pairs of spatially neighboring cells within a 10 micron radius. Next, we performed multinomial logistic regression²⁴⁹ separately for each possible cell state, estimating the probability of the neighboring cell state identity given patient group. Specifically, let Y_{in} denote the subcluster identity of the n_{th} neighbor to cell i . The regression model estimates $\Pr(Y_{in} = k \mid G_i)$, where G_i denotes the patient group of cell i (non-responder, partial responder, or complete responder), and k denotes cell state category.

For each modeled subcluster, we identified cell state pairs with differential colocalization probability between patient groups using the *emmeans* R package.³⁰

Response group specific ecosystems

First a filter was applied to connections where Estimated Pr(neighbor subcluster) is greater in CR than in both NR and PR. Secondly a filter was applied to connections where at least one of the comparisons (CR vs. NR) or (CR vs. PR) is significant ($p < 5.9e-6$). “Enriched in CR cells” indicates that the subcluster has significantly higher frequency in CR ($P < 0.05/98$ subclusters) compared to NR and PR across all subclusters. The analogous filters were used to describe PR and NR response group ecosystems.

Validation with other single-cell datasets

Single-cell datasets were obtained from public repositories, and an overview of the external datasets and their characteristics is provided in **Supplemental Table 2**. These datasets included an immune cell compendium from Domínguez Conde³¹, colon data from Kong³², breast cancer data from Bassez³³, head and neck cancer data from Franken³⁴ and a large dataset of 30 cancer types and their corresponding normal tissues from Kang³⁵. The transfer functionality from the Seurat package was used to transfer CosMx cell types on these external datasets. Main cell types with a maximal prediction score < 0.4 were considered unassigned. Cell subtypes were also considered unassigned if the parent cell type did not match that of the child cell type. Transfer of cell types was done for each dataset separately. Cell type allocation in the current and external data were compared. For each cell (sub)type the overlap with the cell type in the external data was calculated as percentage of all cells identified as a cell type as identified in the current study.

A paired Wilcoxon rank test was used to identify statistically significant differences between paired pre- and on-treatment samples in the TNBC and HNC cohorts.^{253 254} To identify differences in the ratio of cell types identified as supportive versus non-supportive for immunotherapy, the total number of supportive cells was divided by the total number of non-supportive cells. A positive ratio would indicate a higher fraction of supportive cells versus non-supportive cells. For a direct comparison of supportive cells versus non-supportive cells, we compared the percentages of supportive and non-supportive cells relative to the total number of cells measured in a patient.

Results

Digital reconstruction of a vHSIL cell atlas shows high diversity across patients.

Formalin-fixed paraffin-embedded vHSIL biopsies of 20 patients prior to immunotherapeutic vaccination who displayed a complete response (CR; n=6), partial response (PR; n=7) or no clinical response (NR; n=7)^{10 11} (**Table 1**), were analyzed at the single-cell transcriptomic level with the validated CosMx Spatial Molecular Imager using a 1000-plex RNA panel (**Supplemental Table 3**).¹⁹ A total of 65 fields of view with an accumulated area of >36mm² resulted in the detection of 274,878 cells and a mean number of 413 transcripts detected per cell (**Table 2**). Semi-supervised clustering of cells based on their RNA transcriptome (**Supplemental Table 4**) resulted in the identification of 18 different cell types, including 6 types of epithelial cells, fibroblasts, endothelial cells, and several types of lymphocytes and myeloid cells (**Figure 1A, Supplemental Figure 1A**). Cell type neighborhood clustering revealed three epithelial, one stromal, and one stromal-epithelial interface spatial niches with roughly a similar cell count between all patients (**Figure 1B, Supplemental Figure 1BC**).

Table 1. vHSIL cohort patient characteristics.

CosMx study number	Trial study number	Diagnosis	Number of vaccine doses	Systemic T cell response (MoM)	Clinical response at 3 months	Clinical response at 12 months	Trial reference
S10	206	vHSIL	4	16.5	CR	CR	NEJM
S17	503	vHSIL	4	245.5	CR	CR	CCR
S16	531	vHSIL	2	158.4	CR	CR	CCR
S12	532	vHSIL	2	207.4	CR	CR	CCR
S5	509	vHSIL	4	102	PR	CR	CCR
S11	563	vHSIL	3	178.7	PR	CR	CCR
S8	201	vHSIL	4	96.5	PR	PR	NEJM
S9	510	vHSIL	4	48.7	PR	PR	CCR
S13	512	vHSIL	4	78.2	PR	PR	CCR
S19	529	vHSIL	4	186.4	PR	PR	CCR
S18	530	vHSIL	3	195.3	PR	PR	CCR
S1	203	vHSIL	4	40.8	NR	PR	NEJM
S2	526	vHSIL	2	214	NR	PR	CCR
S15	228	vHSIL	4	61.4	NR	NR	NEJM
S7	519	vHSIL	4	194.5	NR	NR	CCR
S14	522	vHSIL	4	106.6	NR	NR	CCR
S6	524	vHSIL	4	68.1	NR	NR	CCR
S20	528	vHSIL	4	126.5	NR	NR	CCR
S3	202	vHSIL	4	2.9	NR	NR	NEJM
S4	517	vHSIL	4	161.5	NR	NR	CCR

vHSIL = vulvar high-grade squamous intraepithelial lesion
MoM = median of maximum. The MoM value was calculated by taking the median of the highest specific IFNy ELISpot counts against HPV16 E6 and E7 peptides per blood sample obtained during and after immunotherapeutic vaccination, so that one value could be obtained for the systemic T cell response per individual patient. NEJM reference[10]: Kenter et al (2009). Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. *N Engl J Med*, 361(19), 1838-1847. <https://doi.org/10.1056/NEJMoa0810097>
CCR reference[11]: Van Poelgeest et al (2016). Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response. *Clin Cancer Res*, 22(10), 2342-2350. <https://doi.org/10.1158/1078-0432.Ccr-15-2594>

Table 2. CosMx data metrics.

	Complete responders	Partial responders	Non-responders	Full cohort
Number of fields of view (FOVs)	29	17	19	65
Area measured (mm²)	16.43	9.63	10.76	36.82
Number of cells	121,877	62,573	90,428	274,878
Total transcripts	61,739,516	23,399,624	38,913,342	124,052,482
% Of cells with >20 counts	98.08	97.45	98.13	97.95
Mean transcripts per cell	473	323	396	413
Assigned transcripts (%)	93.28	86.34	92.14	91.61
Genes detected above LOD	586	599	609	611
Cellular transcripts per μm^2	3.8	2.4	3.6	3.4
Mean negatives per cell	1.59	1.30	1.43	1.47

The 6 different epithelial cell types were characterized based on their specific keratin expression³⁶ into basal cells, suprabasal cells, activated keratinocytes, contractile keratinocytes, differentiating and fully differentiated keratinocytes (**Supplemental Figure 1DE**). All together this allowed us to digitally reconstruct vHSIL lesions (**Figure 1CD**). Moreover, we validated the concordance between keratin expression at the protein and gene transcript level (**Figure 1E**). The proportion of each epithelial cell type present in the vHSIL lesion differed per patient, sustaining the notion that the disease manifests differently across patients, but no immunotherapy response-specific pattern was found (**Supplemental Figure 1FG**). This was also the case when the proportions of the other cell types were analyzed (**Supplemental Figure 1H**). Thus, these data reveal vast heterogeneity between patients with a tumor that all had the same etiological background and originated in the same anatomical location.




Figure 1. Cellular composition of vHSIL decomposed by spatial single-cell transcriptomics. Archived FFPE tissue sections obtained from vHSIL patients (n=20) before therapeutic vaccination with an HPV16 synthetic long peptide vaccine, were subjected to single-cell spatial transcriptomics. Upon vaccination, 6 patients showed a complete response (CR), 7 a partial response (PR) and 7 no response (NR). **A)** UMAP plot containing 274,878 cells resulted in the identification of 18 cell clusters. **B)** Representative vHSIL CosMx image after cell segmentation and tissue segmentation, indicating the 5 spatial niches (3 epithelial niches, 1 stromal niche, and 1 stroma-epithelium interface niche). **C)** Representative images of the spatial location of different types of epithelial cells, fibroblasts, endothelial cells and different immune cells. **D)** Full reconstruction of tissue section by spatially overlaying all cell clusters. **E)** Comparison of pan-cytokeratin (PanCK) protein detection by immunofluorescence (antibody clone NB2-33200AF532, Novus) and RNA detection, showing a good overlay between protein and RNA detection.

Identification and validation of different cell states.

To dissect the diversity of the different cell types within the TME and between patients, the non-epithelial cell types were further subclustered based on the set of genes higher expressed in that specific cell type when compared to all other cells (**Supplemental Table 4**). This resulted in the identification of a total of 99 subclusters among endothelial cells (n=10), fibroblasts (n=10), CD4 T cells (n=11), CD8 T cells (n=8), Tregs (n=8), B cells (n=6), plasma cells (n=9), myeloid DCs (n=9), plasmacytoid DCs (n=6), macrophages (n=10), neutrophils (n=3), and mast cells (n=8) (**Supplemental Figure 2**). To ascertain whether the cell (sub)types identified were specific for vHSIL, their presence was assessed in several publicly available datasets with large numbers of cells analyzed^{32 33 35}, and an immune cell compendium³¹ (**Supplemental Table 2**). This not only successfully verified cell (sub)type identity (**Figure 2A, Supplemental Figure 3**) but also revealed that almost all identified immune cell subtypes in vHSIL, were also present in other tissues, including a series of other healthy tissues and cancer types (**Supplemental Figure 4**). The multiple different functional cell states of the cell types were derived by analysis of the cluster defining genes and literature (**Supplemental Table 5**). Based on the comparison with the other datasets, and marker gene expressions, some cell types were manually corrected (pDC_5, B cell_0 and 4, E_5), also showing that CD4_5 belonged to the Treg subclusters.




Figure 2. Validation of cell types and cell states specific for clinical response to immunotherapeutic vaccination.

A) To validate the existence of the identified 18 cell clusters, their transcriptome was compared to large numbers of single-cells present in several publicly available datasets: Kong³², Bassez³³ and Kang³⁵, showing high concordance between the identified cell clusters in this study versus that of the public databases.

B) Heatmaps showing the cell states that are specifically enriched (Z-test for difference in proportion, Bonferroni corrected) in complete responders (CR, n=6), partial responders (PR, n=7) and non-responders (NR, n=7) therapeutic vaccination, and compared to their presence in the other response groups. The color legend indicates the proportion of each cell state within the major cell type. The explanation of the cell type abbreviations can be found in Supplemental Table 5.

Balance between vaccine supportive and non-supportive cell states differs per clinical response.

A comparison between the frequencies of the different cell types and their states in the lesions of CR, PR and NR patients was made to assess whether differences in clinical response were associated with the composition of the lesions before immunotherapy. This response group comparison revealed higher proportions of CD8⁺CD103⁺ tissue resident effector cells (CD8_6), CD4⁺CD161⁺ effector cells (CD4_6), phagocytic M1 macrophages (M_3),

classically activated DCs (mDC_7), cDC2s (mDC_8), GZMB⁺, IFN-activated pDC (pDC_0), inflammatory mast cells (mast_1), T cell infiltration supportive *IGFB7*hi endothelial cells³⁷ (E_8/9) and immunity supportive fibroblasts (F_2/3/4/5/8) amongst others in complete responders to immunotherapy (**Figure 2B**).

In contrast, the lesions of partial responders comprised higher proportions of type 2 cytokine CD4⁺ T cells (CD4_3, CD4_4) and *CCL18*-expressing macrophages (M_6), known to attract type 2 T cells and Tregs.³⁸⁻⁴⁰ Non-responding lesions showed preferential infiltration with non-activated immune cells (CD8_3, CD4_0, M_0, mDC_4) and potentially suppressive fibroblasts (F_6/7/9) when compared to the other response groups (**Figure 2B**).

For many subclusters, but not all, their transcriptome allowed to propose a potential positive or negative direction of their effect on immunotherapy, based on our current knowledge of tumor-immunity (**Supplemental Table 5**). The variation in the proportion of each individual cell type and cell state among the patients in each response group (**Supplemental Figure 5**) suggested that rather than a difference in one specific cell type or cell state, it is the overall balance between the anticipated effect of all cell states present in the lesion that may influence clinical outcome. Indeed, while the proportions of cells with a supportive effect on immunotherapy were found in balance with the proportions of non-supportive cells in the CR group, the proportion of cells negatively impacting immunotherapy was higher in the PR and NR patient groups (**Figure 3**). CR lesions exhibited a higher ratio of immune-supportive to immune-suppressive cells, compared to PR and NR lesions (**Figure 3**).




Figure 3. The balance between vaccination supportive and non-supportive cells differs per vaccine response group.

For many subclusters, their transcriptome allowed to identify them as potentially supportive or non-supportive for immunotherapy (Supplemental Table 5). Cells classified as supportive were: CD4_6/9/10; CD8_1/6/7; M_2_1/3/4/5; mDC_2/3/7/8; pDC_4; Mast_1/3; F_2/3/5/8; E_2/6/8/9/10. Cells classified as non-supportive were: CD4_0/3/4; Tregs; CD8_0/3/5; mDC_1_4; M2_0/1/6/7/8/9; pDC_1/2/3; Mast_2/5; F_1/6/7/9; E_7. The explanation of the cell type abbreviations can be found in Supplemental Table 5. **A**) Two representative CosMx images per response group in which the immunotherapy supportive cells (upper image) and the immunotherapy non-supportive cells (lower image) are visualized in situ. Epithelial cells are also shown for reference. **B**) The ratio of therapeutic vaccine supportive versus non-supportive cells was determined in complete responders (CR), partial responders (PR) and non-responders (NR) to therapeutic vaccination. Ratio >1 indicating an excess of supportive cells, <1 indicating an excess of non-supportive cells. **C**) The average proportion of total cells classified either as supportive (green) or non-supportive (red) in the groups of CR, PR and NR patients. Statistical significance is calculated with the Z-test for difference in proportion, and indicated with asterisks: * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$. **D**) The proportion of total cells classified either as supportive (green) or non-supportive (red), present per individual patient. CR, $n = 6$, PR, $n = 7$, NR, $n = 7$.

Presence and response of detected immune cell states after immune checkpoint blockade.

We identified two patient cohorts who received neoadjuvant checkpoint blockade therapy, of which single-cell transcriptomics data on all cell types present in the TME were available. In the first cohort, patients with triple negative breast cancer (TNBC) were treated with anti-PD1 prior to surgery ³³. In the second cohort, the effect of neoadjuvant anti-PDL1 with or without anti-CTLA4 was studied in advanced resectable head and neck squamous cell carcinoma (HNC) ³⁴. We interrogated these datasets for the presence and response to checkpoint blockade of the immune cell states detected in the vHSIL lesions by a comparison of the frequencies of all these cells in the TME before neoadjuvant checkpoint therapy and at surgery.

In both cohorts, checkpoint blockade resulted in the increased detection of the immune supportive CD4⁺CD161⁺ effector cells (CD4_6) and activated chemotactic CD8⁺ cells (CD8_7), while a decrease was observed in the non-supportive population of suppressive CD8⁺ cells (CD8_0) (**Figure 4AB**). In addition, in both cohorts a decreased presence of non-supportive fibroblasts (F_1, F_6, F_7) was observed (**Figure 4AB**). There were also treatment group specific changes in immune supportive and non-supportive cell states found. In the TNBC cohort an increase in immune supportive proliferating CD4⁺ cells (CD4_9) and chemotactic macrophages (M_5) was observed after checkpoint blockade, while for the immune non-supportive populations an increase in Tregs (Treg_1, Treg_4) and a decrease in CD8_3 cells was found (**Figure 4AB**). In the HNC cohort the decrease of DC-like macrophages (mDC_3) and IGFB7⁺ endothelial cells (E_8) was observed after treatment (**Figure 4AB**).




Figure 4. The response of identified cell states upon checkpoint blockade.

*Neoadjuvant checkpoint blockade altered the proportion of several of the identified cell states present in the TME of **A**) patients with triple negative breast cancer (TNBC) ³³, and **B**) patients with advanced resectable head and neck squamous cell carcinoma (HNC) ³⁴. Boxplots show the proportion of those cells that significantly shifted after checkpoint blockade.*

*The ratio of immunotherapy supportive versus non-supportive cells was determined **C**) in the TNBC cohort and **D**) in the HNC cohort, before and after checkpoint blockade therapy. Boxplots depict this ratio, and how it changes upon immunotherapy, with paired patient data (lines connecting the same patient). Statistical significance is calculated with the Wilcoxon rank test, and indicated with asterisks: * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$. The explanation of the cell type abbreviations can be found in Supplemental Table 5. **E, F**) The shift in the proportion of immunotherapy supportive and non-supportive cells before and after checkpoint blockade was visualized by scatter plots, showing a specific increase in the proportion of immunotherapy supportive cells upon checkpoint blockade therapy (vertical shift of the cloud upon therapy), while the proportion of non-supportive cells did not change upon therapy (no horizontal shift).*

The consistent increase in CD4⁺CD161⁺ effector cells (CD4_6), the activated chemotactic CD8⁺ cells (CD8_7) and decrease in the non-supportive population of suppressive CD8⁺ cells (CD8_0) cells single these cell states out as cells that are particularly being modulated by immune checkpoint therapy, irrespective of the checkpoint blocking antibody used. However, tumor type- and/or therapy-specific changes in immune supportive and non-supportive cell states were also found. To assess if checkpoint therapy displayed an overall positive effect on the proportion of immune supportive cells in the TME, we interrogated the data of these two cohorts with respect to the balance between immunotherapy supportive and non-supportive cells. In both cohorts the ratio between supportive and non-supportive cell states increased, indicating a shift towards a higher presence of immune-supportive cells in the TME after checkpoint blockade (**Figure 4CD**). Scatter plots showing the percentage of all supportive and non-supportive cell states in the TME for the patients before and after checkpoint blockade therapy shows a treatment-associated shift upwards above the diagonal, indicating that the enhanced ratio mostly is due to an increased percentage of immune supportive cell states upon treatment (**Figure 4EF**). Overall, these data indicate that checkpoint blockade is associated with significant alteration of the TME in favor of effective anti-tumor immunity and suggests a more prominent role for the CD4⁺CD161⁺ effector cells (CD4_6) and the activated chemotactic CD8⁺ cells (CD8_7) in this treatment.

Spatial ecosystems prime the patient's clinical response to immunotherapy.

The abundancy of specific cell states from a variety of cell types in each response group can reflect different functional ecosystems in which different cells may play a role to build the ecosystem and/or interact to achieve a particular functional outcome within the ecosystem. We performed a 10µm distance neighborhood analysis to capture potential interactions between

cells that were significantly enriched in one clinical response group when compared to the other two response groups of vHSIL patients. In the CR group a central role was found for CXCL14⁺ reticular fibroblasts (F_3), known to foster immune cell infiltration⁴¹, displaying clustering with many types of T cells and dendritic cells (**Figure 5A, Supplemental Figure 6A**). CXCL14 is a chemokine with both pro-tumor (inducing M2 proliferation of macrophages, stimulating angiogenesis) and anti-tumor (chemotaxis of dendritic cells and natural killer cells) capacities, depending on the context.⁴²⁻⁴⁴ High numbers of CXCL14-expressing fibroblasts have previously been found to be associated with response to immune checkpoint blockade in renal cell carcinoma⁴⁵, and with improved anti-tumor immunity in glioma⁴⁶. Moreover, there was an enrichment of multiple specific cell states, including that of effector T cells (CD4_6; CD8_6), phagocytic macrophages (M_3), pDC_0, Tregs and of a T cell infiltrating supporting endothelial (E_8) subset³⁷ more preferentially present in the CR than in the PR and NR group and with a higher probability to form the ecosystem (**Figure 5**).




Figure 5. Pre-existing cellular ecosystems are specific for the response to therapeutic vaccination.

To capture potential cellular interactions, a 10 μ m distance neighborhood analysis was performed on the single-cell spatial transcriptomics data of the complete responders (CR, n=6), partial responders (PR, n=7) and non-responders (NR, n=7) in the vHSIL cohort treated with therapeutic vaccination.

A) Spatial cellular interaction networks ('ecosystems') that are specific for therapeutic vaccine-induced CR, PR and NR are shown. A triangle indicates cell types with a cell frequency that is specifically enriched in that response group, a circle indicates those that are not specifically enriched. The color of the connecting line reflects the level of significance and indicates how prominent the spatial interaction is in that response group, calculated by multinomial logistic regression (comparing the connection for pairs of subclusters between groups). The legend for the corresponding p-values is provided as a colored box. For CR: orange line indicates significantly increased compared to PR, blue line indicates significantly increased compared to NR. For PR: orange line indicates significantly increased compared to NR, blue line indicates significantly increased compared to CR. For NR: orange line indicates significantly increased compared to PR, blue line indicates significantly increased compared to CR. **B)** Visualization of the cells forming the CR, PR or NR characteristic ecosystems in a representative CR, PR and NR FFPE vHSIL section. Epithelial cells are also shown for reference. The explanation of the cell type abbreviations can be found in Supplemental Table 5.

In the PR group a central role was found for two CD4 cell states (CD4_3 and CD4_4) interacting with many different states of dendritic cells and macrophages (**Figure 5B**). In particular, two CD4⁺ T cell states associated with type 2 cytokine production clustered at higher probability with CCL18-expressing (M_6) macrophages, fibroblasts_1, suppressive mDC_1 and Tregs (CD4_5 and Tregs) compared to patients with CR or NR (**Figure 5**). As literature shows that especially CCL18⁺ macrophages activate fibroblasts^{47 48}, we investigated the correlation between the CCL18⁺ macrophages (M_6) and fibroblasts. Indeed, a direct relationship was found between the presence of CCL18⁺ macrophages (M_6) and fibroblasts in PR patients ($r = 0.97$, $P = 0.0003$), but not in NR ($r = -0.17$, $P = 0.71$) or CR ($r = -0.24$, $P = 0.65$) (**Supplemental Figure 6B**). Yet, when the correlation between macrophage_6 and the various fibroblast subtypes was examined, we found that the presence of CCL18⁺ macrophages was specifically related to the presence of the fibrosis enhancing subtype fibroblasts_1 in all response groups (PR, $r = 0.95$, $P = 8.7 \times 10^{-4}$; NR, $r = 0.86$, $P = 0.01$; CR, $r = 0.79$, $P = 0.06$) but most pronounced in the PR patient group (**Supplemental Figure 6C**) and fitting with the fact that this patient group displayed the strongest influx with CCL18⁺ macrophages. This confirms that CCL18, but in particular CCL18 expressing macrophages being the most dominant cell type expressing CCL18 (**Supplemental Figure 6D**), induce immunosuppressive fibroblasts.

The CR- and PR-specific spatial ecosystems clearly differed from the one found in the NR group as in the latter group specific enrichment of interactions between non-supportive fibroblasts (F_6) and macrophages (M_0) and Tregs was found (**Figure 5**). These data demonstrate the presence of specific spatial ecosystems in vHSIL, of which the organization of tumor-immunity supporting cell clusters in CR clearly differ from the predominantly type 2

cytokine response-supporting cell clusters organized in PR, and from the absence of specific immune cell clusters in NR. This suggests that the type of cellular ecosystem present in treatment naïve vHSIL supports or restrains the clinical response to immunotherapeutic vaccination. Analysis of two pre- and post-vaccination vHSIL biopsies sustained this notion, showing an increased Th2 and a decreased Th1 outgrowth in a PR patient, but not in a CR patient, despite a similar strong systemic vaccine-induced IFN γ response mediated predominantly by CD4 T cells (**Supplemental Figure 7**).

Discussion

Leveraging single-cell spatial transcriptomics in a clinically driven approach, we addressed a fundamental question in cancer research: the complexity and heterogeneity of the tumor microenvironment and its impact on immunotherapy responsiveness. Our analysis revealed that the complexity and diversity of cellular states in the TME varies significantly between patients, even among those with similar clinical outcomes. Specifically, the proportion of cells potentially supportive or non-supportive to anti-tumor immunity differs across patients and there was no consistent association between specific cell types and clinical response to immunotherapeutic vaccination. Instead, the TME of patients who achieved complete regression displayed a specific ecosystem in which inflammatory cells capable of supporting vaccine-driven anti-tumor responses closely interacted. In partial responders the TME comprised a mixed type 1 and type 2 cellular environment which was specifically dominated by close interactions between type 2 immune cells, generally less effective at supporting anti-tumor immunity.⁴⁹ Our findings also show that neoadjuvant immune checkpoint therapy altered the balance between immune-supportive and non-supportive cell states within the TME, specifically increasing the proportion of immune-supportive cells. These observations underscore the broader clinical relevance of our data.

This study investigates the TME of patients treated with an immunotherapeutic vaccine. Over five decades of research have driven substantial progress in therapeutic cancer vaccine development, including the improved identification of tumor-specific antigens, the engineering of highly immunogenic platforms, and the integration of vaccines with immune checkpoint blockade therapies. These advancements are now bolstered by reliable methods for assessing vaccine pharmacodynamics.^{1 50} Despite these innovations, the identification

of robust predictive biomarkers for clinical success remains a pivotal unmet need. While vaccine-induced immune responses often correlate with clinical activity in trials^{1 17 50-53}, pinpointing specific cellular or molecular biomarkers has proven challenging. This is likely due to the complexity and heterogeneity of the TME, where cell types, cell states, and their spatial interactions exhibit significant interpatient heterogeneity. Our findings underscore the importance of analyzing the TME in its spatial context to unravel this complexity. This spatially informed perspective may transform how we evaluate and stratify patients in immunotherapy, enabling tailored interventions with greater clinical impact.

Our data suggest that the overall balance between immune-supportive and restraining cells in the TME—spanning lymphocytes, myeloid cells, fibroblasts, and endothelial cells—determines vaccine efficacy. Moreover, our findings indicate that distinct cellular ecosystems, rather than isolated cell types, govern the lesion's susceptibility to immunotherapeutic vaccination. An ideal therapeutic vaccine amplifies tumor-specific type 1 cytokine-producing CD4+ and CD8+ T cells.^{1 54} However, PR patients exhibited ecosystems enriched with type 2 cytokine-producing CD4+ T cells (CD4_3, CD4_4), which interacted with Th2-attracting macrophages (M_6), wound-healing fibroblasts (F_1), and certain dendritic cells (mDC_1). This Th2-dominant environment may undermine vaccine-driven anti-tumor responses, despite the presence of robust systemic Th1/Th2 immunity post-vaccination¹⁷.

The presence of distinct ecosystems explaining variable clinical outcomes is consistent with observations in preclinical and clinical models. For example, recent murine studies demonstrated that a spatial triad of CD4+ T cells, CD8+ T cells, and dendritic cells is critical for both anti-tumor immunity and responsiveness to checkpoint inhibitors.⁵⁵ Similarly, Luca et al. identified carcinoma ecosystems (CEs) across 16 human cancers.⁵⁶ Two distinct ecosystems, CE9 and CE10, have been strongly associated with favorable clinical outcomes, including longer overall survival, spontaneous regression of premalignant lung lesions (CE10), and positive responses to checkpoint blockade therapy (CE9). The differential association of CE9 and CE10 with specific clinical outcomes underscores the concept of therapy-specific ecosystems. Consistent with this, the CR-associated ecosystem identified in our study shares several cellular states with CE9 and CE10. For example, DC_S1 and mDC_2 correspond to cDC1; DC_S3 (CD80, CD274) aligns with mDC_7; CD8_S1 (GZMK) matches CD8_3; CD8_S3 (GZMB) is similar to CD8_6; Mast S4 (TPSAB1, TPSB2, CPA3) corresponds to Mast_1; CD4_S1 (IL2RA, CTLA-4, Foxp3, TIGIT) resembles Tregs/


CD4_5; and CD4_S2 (IL7R) aligns with CD4_6. Importantly, our findings also revealed the enriched presence of cDC2 (mDC_8), phagocytic M1 macrophages (M_3), a unique fibroblast state (F_3), and several IGFBP7^{hi} endothelial cell states in CR patients, further illustrating ecosystem-level differences linked to clinical outcomes.

These results extend our understanding of T cell-based immunotherapy, highlighting conserved cellular features across various treatment modalities. One prominent example is the enrichment of CD161(KLRB1)+CD4+ Th1 effector cells in CR patients from our vaccine cohort. This cell population was similarly enriched in responders with triple-negative breast cancer (TNBC) and head and neck cancer (HNC) treated with PD1 or PDL1 checkpoint blockade.^{33 34} Our previous work described this CD161+CD4+ effector memory subset in tumors exhibiting active anti-tumor T cell responses.⁵⁷ These cells are characterized by their ability to produce key effector cytokines, including IFN γ and TNF α ,¹⁶ and their rapid response to antigen recognition compared to CD161-negative counterparts⁵⁸. Moreover, increased numbers of intratumoral CD161+CD4+ effector cells are strongly correlated with improved survival in multiple cancers, including HNC.^{16 58} Collectively, these observations underscore the pivotal role of this CD4+ T cell population in driving effective immunotherapy responses.

Another key finding is the presence of cells producing immune cell homing cytokines, which were detected in both partial and complete responders. Specifically, we identified a subset of CD4+ T cells (CD4_2) expressing IL16, a cytokine known to recruit monocytes, dendritic cells, and T cells into lesions.⁵⁹⁻⁶¹ In vHSIL, CD4_2 cells were spatially interacting with effector cells, including CD4_6 and CD8_6. In checkpoint blockade cohorts, treatment increased the prevalence of CD8+ T cells (CD8_7) producing the chemokines CCL3 and CCL4, which attract various myeloid cell types and T cells.^{62 63} Recent evidence also demonstrates that CCL3 and CCL4-producing CD8+ T cells infiltrate tumors upon therapeutic vaccination, driving the recruitment and activation of phagocytic M1-like macrophages, ultimately leading to complete tumor regression.⁶⁴ Based on their cellular interactions within the CR ecosystem and functional roles described in the literature, several other cell states are likely to positively influence clinical outcomes following immunotherapy. While the contribution of these states remains to be fully elucidated, the importance of CD161+ Th1 cells (CD4_6), chemotactic CD8+ T cells (CD8_7), CD8+CD103+ tissue-resident effector cells (CD8_6), and phagocytic M1 macrophages (M_3) has been firmly established.⁶⁵

The study also identified macrophages expressing CCL18, a marker of alternatively activated macrophages within Th2-dominant environments.⁶⁶ While CCL18 may directly boost tumor growth⁶⁷, its production also leads to the preferential attraction of Th2-like cells and Tregs^{39 40}, both enriched in PR patients. The presence of these macrophages was connected to that of Th2 cells, both of which were predominantly found in patients with a partial response upon therapeutic vaccination. Previously, we have shown that vaccination led to the activation of both Th1 and Th2 CD4+ T cells, and in a vHSIL patient case with a PR we were able to show that only tumor-specific Th2 cells could be cultured from the lesion after vaccination.¹⁷ Our study thus identified CCL18 as a potential target for co-treatment during therapeutic vaccination. A recently developed *in vivo* active CCL18 blocking peptide⁶⁸ may provide such help.

Supplemental Figures



Supplemental Figure 1. Cell clusters, spatial niches and epithelial cells.

Archived FPPE tissue sections obtained from vHSIL patients (n=20) before therapeutic vaccination with an HPV16 synthetic long peptide vaccine, were subjected to single cell spatial transcriptomics. Upon vaccination, 6 patients showed a complete response (CR), 7 a partial response (PR) and 7 no response (NR).

A) The 18 identified cell clusters and their top characterizing genes.

B) The 5 identified spatial niches (3 epithelial, 1 stromal, 1 stromal-epithelial interface) and the proportions of the various cell types in those spatial niches.




C) The number of cells and proportions per spatial niche per patient. The horizontal line indicates the group-wise proportion.

D) The 6 epithelial cell clusters, and the top genes expressed in those clusters. Highlighted in green are the keratins.

E) Epithelial cell map, showing the various differentiation states of the epithelial cells: basal cells, suprabasal cells, activated keratinocytes, contractile keratinocytes, differentiating and fully differentiated keratinocytes. Adapted from Freedberg et al. J. Invest. Derm. 2001.

F) The number of cells and proportions per epithelial cell cluster per patient.


Chapter 5



Supplemental Figure 1. Continued


G) CosMx images of the 20 individual patients, and the spatial distribution of the 6 identified epithelial cell clusters.

H) The number of cells and proportions per non-epithelial cell cluster (n = 12) per patient.




Supplemental Figure 2. All non-epithelial cell clusters and their highly expressed genes.

On the left, the UMAPs of the non-epithelial cell clusters ($n = 12$) and all their cell states ($n = 99$) are shown. Each dot indicates a single cell, derived from the single cell transcriptomics experiment on treatment naive vHSIL patients ($n = 20$). On the right, the top expressed genes per cell state are shown.



Supplemental Figure 2. Continued



Supplemental Figure 3. Cytokine analyses of the immunotherapeutic vaccine-induced T helper profile.

In vitro assays were performed to study the effector T cell response in vHSIL patients upon therapeutic vaccination.

A) Cytokine responses from vHSIL biopsies pre- and post-immunotherapeutic vaccination, in a CR and PR patient (paired samples, connected by a line). On the left IFN γ , indicative for a T helper 1 response, and on the right IL5, indicative for a T helper 2 response

B) Percentage of HPV-specific T cells by T cell subtype, cultured from vHSIL biopsies pre- and post-immunotherapeutic vaccination, indicating that it is predominantly a CD4+ T cell response.

C) Cytokines derived from freshly cultured antigen stimulated PBMCs post-immunotherapeutic vaccination. The Median-of-Max (MoM) value on the y-axis was calculated by taking the median of the highest specific ELISpot counts per blood sample, so that one value could be obtained for the systemic T cell response per individual patient.

Supplemental Tables

Supplemental Table 2. Characterizing gene set per cell type.

Expected cell type	Gene	Expected cell type	Gene
B cell	MS4A1	pDC	IL3RA
	CD19		GZMB
	CD79A	Plasmablast	JCHAIN
	IGKC		IGHG1
Endothelial	VWF		IGHG2
	PECAM1		IGHM
	RGS5		IGHA1
	SPARCL1		MZB1
Epithelial	KRT5		XBP1
	KRT17	T CD4, T CD8	CD3E
	KRT19		CD3D
	EPCAM		CD3G
Fibroblast	COL1A1	T CD4	IL7R
	COL1A2		STAT4
	COL3A1		TBX21
Macrophage	CXCL8	T CD8	CD8A
	CD68		CD8B
	CD163		KLRK1
	C1QA		GNLY
	C1QB	Treg	GZMA
	C1QC		FOXP3
	LYZ		CTLA4
	MMP9		PDCD1
	IL18		IL32
Mast cell	CPA3		TIGIT
	TPSB2		
	TPSAB1		
	KIT		
mDC	CSF3R		
	CLEC10A		
Neutrophil	IL1B		
	ITGAX		
NK cell	NCR1		

Supplemental Table 4. Characteristics of the validation single cell transcriptomics datasets.

Paper	Tissue	Therapy	Number of patients	Number of cells after QC
Kong, Immunity 2023	Crohn's disease + healthy colon	-	85	413877
Kang, Nature Communications 2024	30 cancer types	-	999	4901584
Bassez, Nature Medicine 2021	Breast cancer	Anti PD1 (pembrolizumab)	31	175942
Franken, Immunity 2024	Head and neck cancer	Anti PD1 (durvalumab) +/- anti CTLA4 (tremelimumab)	20	446380

Supplemental Table 5. Cell state defining genes.

Cluster	Cell abbreviation	Cell state	Cell state defining genes and references	Expected immune impact
CD4 T cells				
0	CD4_0	IFN signalling, low cytotoxic	MX1, OAS1-3, CST7[1]	Non-supportive
1	CD4_1	Non-specified CD4 T cell		
2	CD4_2	Homeotypic cytokine producing	IL-16[2], LTB, MALAT-1[3], CD37[4]	
3	CD4_3	Activated Th2	GATA3, CRIP1[5], RGCC[6], CD44[7], LMNA[8], ANXA3[9]	Non-supportive
4	CD4_4	IL-2 stimulated , activated non-Th1 cells	S100A4[10], S100A6, LGALS1, LMNA[8], VIM[11], CRIP1	Non-supportive
5	CD4_5	Treg with relatively lowered Foxp3	IL2RG, CTLA4, TIGIT, MAF, FOXP3 [12]	
6	CD4_6	Th1 effector cell	IL7R[13], CD28[14], KLRB1[15], TNFRSF12A, CD44[7]	Supportive
7	CD4_7	Non-specified CD4 T cell		
8	CD4_8	Activated suppressive, migratory inhibited Th cell	LAMP3[16, 17], CD83[18, 19], IRF4, RGS1[20]	Non-supportive

Supplemental Table 5 *Continued*

Cluster	Cell abbreviation	Cell state	Cell state defining genes and references	Expected immune impact
9	CD4_9	Proliferating Th cells	VIM, TUBB, HMGB2, COTL1, HP90AA1, CALM1 [21]	Supportive
10	CD4_10	Proinflammatory, proliferating effector Th cell	MALAT1, CRIP1, BATF3[22], CUZD1[23], ICOS[24], IL12, IL17, IL20, IL23	Supportive
Tregs				
0	Treg_0	Long term surviving Tregs	BCL2, BCLXL	Non-supportive
1	Treg_1	Effector Tregs	MAF[25, 26], CTLA-4 [12]	Non-supportive
2	Treg_2	Effector Tregs	SRGN, IL2RG, ICOS [12]	Non-supportive
3	Treg_3	Activated Tregs	EMP3 [27]	Non-supportive
4	Treg_4	Non-specified Treg		Non-supportive
5	Treg_5	Non-specified Treg		Non-supportive
6	Treg_6	Homeostatic Tregs	MX1, PX1 [28]	Non-supportive
7	Treg_7	Effector Tregs	IRF4[29], ICOS, GITR, OX40R	Non-supportive
CD8 T cells				
0	CD8_0	Activated, non type 1, suppressive	S100A6[10], S100A4, LGALS1[30], CRIP1, ANXA1[9]	Non-supportive
1	CD8_1	Terminally differentiated, cytotoxic and T cell chemotactic	STAT4[31], CTSW[32], GNLY, XCL1[33, 34]	Supportive
2	CD8_2	Non-specified CD8 T cells		
3	CD8_3	Low cytotoxic, CCL5 producing	GZMK[35], CST7[1], CCL5	Non-supportive
4	CD8_4	Non-specified CD8 T cells		
5	CD8_5	Innate stimuli responding, proliferation Impaired, terminally differentiated	STAT4, IL12R, IL18R, ITGAL[36], CASP8[37], SIGIRR[38], MALAT1[39]	Non-supportive
6	CD8_6	Activated, cytotoxic, terminally differentiated tissue resident	CD69, PD1, GNLY, GZMB, IL7R, ITGAE, MALAT1[39] [40]	Supportive
7	CD8_7	TCR activated, chemotactic	DUSP2[41], DUSP4[41], TIGIT, CCL3[42, 43], CCL4[42]	Supportive

Cluster	Cell abbreviation	Cell state	Cell state defining genes and references	Expected immune impact
Macrophages				
0	M_0	MHC class II-low non-activated	HLA-DRA, HLA-DRB1, HLA-DPA1, SOD2[44]	Non-supportive
1	M_1	CD163 M2c	CD163[45], Selenop[46], PSAP, MAF, CD36, CD14, CD209, MRC1, C1qa[47]	Non-supportive
2	M_2	Non-defined		
3	M_3	Inflammatory MHC class II-high, phagocytic M1-like	TLR2[48], ITGAV[49], IFNGR, FCGR3a[50], CLEC7a[51], HLA-DRA, HLA-DPA1	Supportive
4	M_4	Proliferating	KI67, RSPO[52], CUZD1[23]	Supportive
5	M_5	TLR activated, chemotactic	RGS1, RGS2, CCL2, CCL3, CCL4, CXCL2, CXCL3	Supportive
6	M_6	Th2 attracting and suppressive M2-like	CCL18[53], CCL13, EMP3[54]	Non-supportive
7	M_7	IL10-induced CD163+ suppressive M2-like	IL10R, LAIR1[55], MAF, CD163 [56]	Non-supportive
8	M_8	Prostaglandin and Galectin-3 M2-like macrophages	PTGDS[57], LGALS3[58] [59, 60]	Non-supportive
9	M_9	GPNMB M2-like macrophages	Cd11c, GPNMB[61], IFNGR1	Non-supportive
Neutrophils				Very low numbers of neutrophils across all samples
0	N_0	Non-specified	CSF3R[62]	
1	N_1	CD16hi, IFN sensing, activated	CD16, MX1, IFITM1, FPR1 [63-65]	
2	N_2	Proinflammatory cytokine producing	IL-8, IL1B, PTPRC, FOS, JUN [66, 67]	
pDC				
0	pDC_0	GZMB+ IFN activated pDC	GZMB[68, 69], GPX1[70], MX1	
1	pDC_1	CCR2+ homeostatic pDC	CCR2[71]	Non-supportive
2	pDC_2	PTGDS+ suppressive pDC	PTGDS[59, 60, 72]	Non-supportive
3	pDC_3	Type II cytokine pDC	PSAP[56]	Non-supportive
4	pDC_4	Translationally active pDC	RPL21, RPL37	

Supplemental Table 5 *Continued*

Cluster	Cell abbreviation	Cell state	Cell state defining genes and references	Expected immune impact
5	pDC_5	NOT pDC	lacks: PLAC8, JCHAIN, IL3A [73]	
mDC				
0	mDC_0	Non-specified mDC		
1	mDC_1	Suppressive DC	EMP3[54], CRIP1[5]	Non-supportive
2	mDC_2	Cross presenting cDC1	BATF3[74-77], IDO1	Supportive
3	mDC_3	T cell attracting DC-like macrophages	CD68, CD14, C1q, CXCL9	Supportive
4	mDC_4	Immature suppressive DC	CD33, RELT[78], CLEC5A[79], IL1RN[80]	Non-supportive
5	mDC_5	SerpinA1+ CLEC10A-cDC2	PSAP, LYZ, CLEC12A, CLEC4A, SERPINA1 [81]	
6	mDC_6	IL1B+ DC	IL1B[82]	
7	mDC_7	CCR7+ mature DC	LAMP3[83], CD83, CD80, CD40, PDL1	Supportive
8	mDC_8	CLEC10A+ cDC2	CLEC10A[81, 84]	Supportive
Mast cells				
0	mast_0	Non-specified		
1	mast_1	Mature inflammatory mast cells	CD44[85], IL1RL1, BTK [86]	Supportive
2	mast_2	Suppressive mast cells	LGALS1[87]	Non-supportive
3	mast_3	Inflammatory mast cells	TNFSF10[88]	Supportive
4	mast_4	Non-specified		
5	mast_5	Mature CD37+ non-inflammatory MC	CD44, LGALS3, CD37 [89]	Non-supportive
6	mast_6	Degranulating monocyte attracting mast cells	CTSG, ATG12, AZU, NPPC [90-92]	
7	mast_7	Activated desensitized mast cells	CD69, LIF, NFKBIA, RGS1, RGS2 [93, 94]	
Plasma cells				
0	P_0	IgA dimer producing activated plasma cells, optimized for TLR mediated Ab production	IGKC, JCHAIN, IGHA1, CD27[95], IRF4[96, 97], HSP90B1[98]	
1	P_1	IgG producing plasma cells	IGKC, IGH1, IGH2, XBP1, MZB1, CD38, FKBP11 [99, 100]	
2	P_2	IgG production inhibited plasma cells	LPAR5[101], LAIR1[102], MPO[103]	

Cluster	Cell abbreviation	Cell state	Cell state defining genes and references	Expected immune impact
3	P_3	AZU1+ IgG+ B cells	IGHG1, AZU1[104]	
4	P_4	igA monomeric producing plasma cell	IGKC, IGHA1	
5	P_5	IgG producing plasma cells	IGKC, IGHG1, IRF4	
6	P_6	Class switching B cells (BATF3) low IgG/A	IGKC, BATF3[105]	
7	P_7	Autophagy-related protein 10+ IgA+ memory B cells	IGHA1, CD27, ATG10	
8	P_8	Cytokine producing IgA+ plasma cells	IGKC, IGHA1, CD79A, IL23A[106], CCL11	
B cells				
0	B_0	NOT B cells	marker genes low (MS4A1, CD19, CD79A, CD27, CD24, IGHx)	
1	B_1	Activated B cells	IL27R, CD80, LTB	
2	B_2	Mature B cells 1	MS4A1, CD79A, CD37	
3	B_3	Naive B cells	TCL1A, IL4R, CXCR4,IGHM, IGHD	
4	B_4	NOT B cells	marker genes low (MS4A1, CD19, CD79A, CD27, CD24, IGHx)	
5	B_5	Mature B cells 2	MS4A1, CD79A, CD37	
Endothelial cells				
0	E_0	Post capillary/high endothelial venule Ecs	VWF, ACKR1 [107-110]	
1	E_1	Non-defined ECs		
2	E_2	HLA class I high ECs	HLA-A, HLA-B, HLA-C, IGFBP7[111]	Supportive
3	E_3	Immature angiogenic ECs	FLT1, KDR, GSN, ENG [107-109, 112, 113]	
4	E_4	Late stage cell differentiated arteriolic ECs	TAGLN, ACTA2, MYL9, MYH11 [107-109, 114]	
5	E_5	NOT ECs	marker genes low (PECAM, VIM) [115]	
6	E_6	Lymphatic ECs	CCL21[116], S100A10, ANXA2, CD9, IGFBP7 [107-109, 112]	Supportive

Supplemental Table 5 *Continued*

Cluster	Cell abbreviation	Cell state	Cell state defining genes and references	Expected immune impact
7	E_7	Arteriolic IGF1+ Notch-signtalling ECs	JAG1, SAT1, EFN2, IGF1, ICAM2[117], IGFBP3[118] [107-109, 119]	Non-supportive
8	E_8	Immature IGFBP7-immune supportive angiogenic ECs	FLT1, KDR, ENG, IGFB7[111], RGCC[120] [107-109, 112]	Supportive
9	E_9	CLEC14a+ angiogenic ECs	CLEC14A[121], CD81, CD9 [107-109, 122]	Supportive
10	E_10	HLA class I high, interferon signalling ECs	IFITM1, MX1, IFI27, OAS3, OAS2, IGFB7[111] [107-109, 123]	Supportive
Fibroblasts				
0	F_0	Non-defined fibroblasts		
1	F_1	Fibrosis enhancing fibroblasts	LUM[124]	Non-supportive
2	F_2	Pericytes/vascular smooth muscle cells	TAGLN, ACTA2, PDGFRB, RGS5 [125-128]	Supportive
3	F_3	Type B CXCL14+ reticular fibroblasts	CXCL12, CXCL14[129], MGP [126, 130]	Supportive
4	F_4	Type A fibroblasts	COL1A1, COL6A1, COL6A2, COL18A1 [126]	
5	F_5	Type B immune stimulatory fibroblasts	CFD, CXCL12, CXCL14[129], IGFBP5[131, 132]	Supportive
6	F_6	Type B/S5 fibroblasts driving type 2 cytokine immunity	CXCL12, CCL2, CCL19, CXCL1, CXCL3, VCAN, MEG3, IGF1, PDGFRA [126, 127, 133]	Non-supportive
7	F_7	Type C prostaglandin producing senescent fibroblast	SPARCL1, CFD, RARRES2, PSAP, PTGDS [126, 134-137]	Non-supportive
8	F_8	Adventitial fibroblasts	APOD, GSN, IGFB6 [138]	Supportive
9	F_9	Non-inflammatory fibroblasts	ZFP36[139], DUSP1	Non-supportive

References of Supplemental Table 5:

Reference number	Reference
1	Prunk, M., et al., <i>Increased cystatin F levels correlate with decreased cytotoxicity of cytotoxic T cells</i> . Radiol Oncol, 2019. 53(1): p. 57-68.
2	Cruikshank, W.W., H. Kornfeld, and D.M. Center, <i>Interleukin-16</i> . J Leukoc Biol, 2000. 67(6): p. 757-66.
3	West, K.A. and D. Lagos, <i>Long Non-Coding RNA Function in CD4(+) T Cells: What We Know and What Next?</i> Noncoding RNA, 2019. 5(3).
4	van Spriel, A.B., et al., <i>A regulatory role for CD37 in T cell proliferation</i> . J Immunol, 2004. 172(5): p. 2953-61.
5	Lanningham-Foster, L., et al., <i>Overexpression of CRIP in transgenic mice alters cytokine patterns and the immune response</i> . Am J Physiol Endocrinol Metab, 2002. 282(6): p. E1197-203.
6	Rus, V., et al., <i>RGC-32 Promotes Th17 Cell Differentiation and Enhances Experimental Autoimmune Encephalomyelitis</i> . J Immunol, 2017. 198(10): p. 3869-3877.
7	Pihlgren, M., et al., <i>Resting memory CD8+ T cells are hyperreactive to antigenic challenge in vitro</i> . J Exp Med, 1996. 184(6): p. 2141-51.
8	González-Granado, J.M., et al., <i>Nuclear envelope lamin-A couples actin dynamics with immunological synapse architecture and T cell activation</i> . Sci Signal, 2014. 7(322): p. ra37.
9	Yang, Y.H., et al., <i>Deficiency of annexin A1 in CD4+ T cells exacerbates T cell-dependent inflammation</i> . J Immunol, 2013. 190(3): p. 997-1007.
10	Jeon, C.H., H.L. Kim, and J.H. Park, <i>Induction of S100A4, S100A6, and galectin-1 during the lineage commitment of CD4+CD8+ thymocyte cell line is suppressed by 2,3,7,8-tetrachlorodibenzo-p-dioxin</i> . Toxicol Lett, 2009. 187(3): p. 157-63.
11	Hornbeck, P.V., et al., <i>Vimentin expression is differentially regulated by IL-2 and IL-4 in murine T cells</i> . J Immunol, 1993. 151(8): p. 4013-21.
12	Mijnheer, G., et al., <i>Conserved human effector Treg cell transcriptomic and epigenetic signature in arthritic joint inflammation</i> . Nat Commun, 2021. 12(1): p. 2710.
13	Patil, V.S., et al., <i>Precursors of human CD4(+) cytotoxic T lymphocytes identified by single-cell transcriptome analysis</i> . Sci Immunol, 2018. 3(19).
14	Linterman, M.A., et al., <i>CD28 expression is required after T cell priming for helper T cell responses and protective immunity to infection</i> . Elife, 2014. 3.
15	Duurland, C.L., et al., <i>CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors</i> . J Immunother Cancer, 2022. 10(1).
16	Shen, D.T., et al., <i>Activation of primary T lymphocytes results in lysosome development and polarized granule exocytosis in CD4+ and CD8+ subsets, whereas expression of lytic molecules confers cytotoxicity to CD8+ T cells</i> . J Leukoc Biol, 2006. 80(4): p. 827-37.
17	Bossi, G. and G.M. Griffiths, <i>Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells</i> . Nat Med, 1999. 5(1): p. 90-6.
18	Liedtke, K., et al., <i>Endogenous CD83 Expression in CD4(+) Conventional T Cells Controls Inflammatory Immune Responses</i> . J Immunol, 2020. 204(12): p. 3217-3226.
19	Reinwald, S., et al., <i>CD83 expression in CD4+ T cells modulates inflammation and autoimmunity</i> . J Immunol, 2008. 180(9): p. 5890-7.
20	Gibbons, D.L., et al., <i>Cutting Edge: Regulator of G protein signaling-1 selectively regulates gut T cell trafficking and colitic potential</i> . J Immunol, 2011. 187(5): p. 2067-71.
21	Oh, D.Y., et al., <i>Intratumoral CD4(+) T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer</i> . Cell, 2020. 181(7): p. 1612-1625.e13.
22	Qiu, Z., et al., <i>Cutting Edge: Batf3 Expression by CD8 T Cells Critically Regulates the Development of Memory Populations</i> . J Immunol, 2020. 205(4): p. 901-906.
23	Leong, C.T., et al., <i>Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro</i> . Oncogene, 2007. 26(6): p. 870-80.

References of Supplemental Table 5 Continued

Reference number	Reference
24	Mahajan, S., et al., <i>The role of ICOS in the development of CD4 T cell help and the reactivation of memory T cells</i> . Eur J Immunol, 2007. 37(7): p. 1796-808.
25	Imbratta, C., et al., <i>c-MAF, a Swiss Army Knife for Tolerance in Lymphocytes</i> . Front Immunol, 2020. 11: p. 206.
26	Wheaton, J.D., C.H. Yeh, and M. Ciofani, <i>Cutting Edge: c-Maf Is Required for Regulatory T Cells To Adopt RORyt(+) and Follicular Phenotypes</i> . J Immunol, 2017. 199(12): p. 3931-3936.
27	Sugimoto, N., et al., <i>Foxp3-dependent and -independent molecules specific for CD25+CD4+ natural regulatory T cells revealed by DNA microarray analysis</i> . Int Immunol, 2006. 18(8): p. 1197-209.
28	Metidji, A., et al., <i>IFN-α/β receptor signaling promotes regulatory T cell development and function under stress conditions</i> . J Immunol, 2015. 194(9): p. 4265-76.
29	Alvisi, G., et al., <i>IRF4 instructs effector Treg differentiation and immune suppression in human cancer</i> . J Clin Invest, 2020. 130(6): p. 3137-3150.
30	Blaser, C., et al., <i>Beta-galactoside-binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells</i> . Eur J Immunol, 1998. 28(8): p. 2311-9.
31	Kaech, S.M. and W. Cui, <i>Transcriptional control of effector and memory CD8+ T cell differentiation</i> . Nat Rev Immunol, 2012. 12(11): p. 749-61.
32	Stoeckle, C., et al., <i>Cathepsin W expressed exclusively in CD8+ T cells and NK cells, is secreted during target cell killing but is not essential for cytotoxicity in human CTLs</i> . Exp Hematol, 2009. 37(2): p. 266-75.
33	Dorner, B., et al., <i>Purification, structural analysis, and function of natural ATAC, a cytokine secreted by CD8(+) T cells</i> . J Biol Chem, 1997. 272(13): p. 8817-23.
34	Dorner, B.G., et al., <i>MIP-1alpha, MIP-1beta, RANTES, and ATAC/lymphotactin function together with IFN-gamma as type 1 cytokines</i> . Proc Natl Acad Sci U S A, 2002. 99(9): p. 6181-6.
35	Jonsson, A.H., et al., <i>Granzyme K(+) CD8 T cells form a core population in inflamed human tissue</i> . Sci Transl Med, 2022. 14(649): p. eabo0686.
36	Liu, X., et al., <i>Endogenous tumor-reactive CD8(+) T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth</i> . Oncoimmunology, 2013. 2(6): p. e23972.
37	Feng, Y., et al., <i>Caspase-8 restricts antiviral CD8 T cell hyperaccumulation</i> . Proc Natl Acad Sci U S A, 2019. 116(30): p. 15170-15177.
38	Wang, Z., et al., <i>Interleukin-37 promotes colitis-associated carcinogenesis via SIGIRR-mediated cytotoxic T cells dysfunction</i> . Signal Transduct Target Ther, 2022. 7(1): p. 19.
39	Kanbar, J.N., et al., <i>The long noncoding RNA Malat1 regulates CD8+ T cell differentiation by mediating epigenetic repression</i> . J Exp Med, 2022. 219(6).
40	Mami-Chouaib, F., et al., <i>Resident memory T cells, critical components in tumor immunology</i> . J Immunother Cancer, 2018. 6(1): p. 87.
41	Tanzola, M.B. and G.J. Kersh, <i>The dual specificity phosphatase transcriptome of the murine thymus</i> . Mol Immunol, 2006. 43(6): p. 754-62.
42	Galeano Niño, J.L., et al., <i>Cytotoxic T cells swarm by homotypic chemokine signalling</i> . Elife, 2020. 9.
43	Allen, F., et al., <i>CCL3 augments tumor rejection and enhances CD8(+) T cell infiltration through NK and CD103(+) dendritic cell recruitment via IFNγ</i> . Oncoimmunology, 2018. 7(3): p. e1393598.
44	Santer, D.M., et al., <i>Plasmacytoid dendritic cells and C1q differentially regulate inflammatory gene induction by lupus immune complexes</i> . J Immunol, 2012. 188(2): p. 902-15.
45	van Elsas, M.J., et al., <i>Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy</i> . J Immunother Cancer, 2023. 11(3).
46	Baxter, E.W., et al., <i>Standardized protocols for differentiation of THP-1 cells to macrophages with distinct M(IFNγ+LPS), M(IL-4) and M(IL-10) phenotypes</i> . J Immunol Methods, 2020. 478: p. 112721.

Reference number	Reference
47	Revel, M., et al., <i>C1q+ macrophages: passengers or drivers of cancer progression</i> . Trends Cancer, 2022. 8(7): p. 517-526.
48	Kakutani, R., et al., <i>Essential role of Toll-like receptor 2 in macrophage activation by glycogen</i> . Glycobiology, 2012. 22(1): p. 146-59.
49	Antonov, A.S., et al., <i>$\alpha V\beta 3$ integrin regulates macrophage inflammatory responses via PI3 kinase/Akt-dependent NF-κB activation</i> . J Cell Physiol, 2011. 226(2): p. 469-76.
50	Boyle, J.J., <i>Human macrophages kill human mesangial cells by Fas-L-induced apoptosis when triggered by antibody via CD16</i> . Clin Exp Immunol, 2004. 137(3): p. 529-37.
51	Wang, Y., et al., <i>Clec7a expression in inflammatory macrophages orchestrates progression of acute kidney injury</i> . Front Immunol, 2022. 13: p. 1008727.
52	Nagano, K., et al., <i>R-spondin 3 deletion induces Erk phosphorylation to enhance Wnt signaling and promote bone formation in the appendicular skeleton</i> . Elife, 2022. 11.
53	Islam, S.A., et al., <i>Identification of human CCR8 as a CCL18 receptor</i> . J Exp Med, 2013. 210(10): p. 1889-98.
54	Kusumoto, Y., et al., <i>Epithelial membrane protein 3 (Emp3) downregulates induction and function of cytotoxic T lymphocytes by macrophages via TNF-α production</i> . Cell Immunol, 2018. 324: p. 33-41.
55	Xie, J., et al., <i>Blocking LAIR1 signaling in immune cells inhibits tumor development</i> . Front Immunol, 2022. 13: p. 996026.
56	Ghassabeh, G.H., et al., <i>Identification of a common gene signature for type II cytokine-associated myeloid cells elicited in vivo in different pathologic conditions</i> . Blood, 2006. 108(2): p. 575-83.
57	Tsubosaka, Y., et al., <i>Hematopoietic prostaglandin D synthase-derived prostaglandin D(2) ameliorates adjuvant-induced joint inflammation in mice</i> . Faseb j, 2019. 33(6): p. 6829-6837.
58	Novak, R., S. Dabelic, and J. Dumic, <i>Galectin-1 and galectin-3 expression profiles in classically and alternatively activated human macrophages</i> . Biochim Biophys Acta, 2012. 1820(9): p. 1383-90.
59	Joo, M. and R.T. Sadikot, <i>PGD synthase and PGD2 in immune response</i> . Mediators Inflamm, 2012. 2012: p. 503128.
60	Sarashina, H., et al., <i>Opposing immunomodulatory roles of prostaglandin D2 during the progression of skin inflammation</i> . J Immunol, 2014. 192(1): p. 459-65.
61	Zhou, L., et al., <i>Glycoprotein non-metastatic melanoma protein b (Gpnmb) is highly expressed in macrophages of acute injured kidney and promotes M2 macrophages polarization</i> . Cell Immunol, 2017. 316: p. 53-60.
62	Dwivedi, P. and K.D. Greis, <i>Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies</i> . Exp Hematol, 2017. 46: p. 9-20.
63	Golay, J., et al., <i>Human neutrophils express low levels of FcγRIIIA, which plays a role in PMN activation</i> . Blood, 2019. 133(13): p. 1395-1405.
64	Coppolino, M.G., et al., <i>Evidence for a molecular complex consisting of Fyb/SLAP, SLP-76, Nck, VASP and WASP that links the actin cytoskeleton to Fcγ receptor signalling during phagocytosis</i> . J Cell Sci, 2001. 114(Pt 23): p. 4307-18.
65	Dorward, D.A., et al., <i>The role of formylated peptides and formyl peptide receptor 1 in governing neutrophil function during acute inflammation</i> . Am J Pathol, 2015. 185(5): p. 1172-84.
66	Mihaila, A.C., et al., <i>Transcriptional Profiling and Functional Analysis of N1/N2 Neutrophils Reveal an Immunomodulatory Effect of S100A9-Blockade on the Pro-Inflammatory N1 Subpopulation</i> . Front Immunol, 2021. 12: p. 708770.
67	Pellmé, S., et al., <i>Localization of human neutrophil interleukin-8 (CXCL-8) to organelle(s) distinct from the classical granules and secretory vesicles</i> . J Leukoc Biol, 2006. 79(3): p. 564-73.
68	Jahrsdörfer, B., et al., <i>Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion</i> . Blood, 2010. 115(6): p. 1156-65.
69	Haque, A., et al., <i>Granzyme B expression by CD8+ T cells is required for the development of experimental cerebral malaria</i> . J Immunol, 2011. 186(11): p. 6148-56.

References of Supplemental Table 5 Continued

Reference number	Reference
70	Oberkampf, M., et al., <i>Mitochondrial reactive oxygen species regulate the induction of CD8(+) T cells by plasmacytoid dendritic cells</i> . Nat Commun, 2018. 9(1): p. 2241.
71	Cédile, O., et al., <i>The chemokine receptor CCR2 maintains plasmacytoid dendritic cell homeostasis</i> . Immunol Lett, 2017. 192: p. 72-78.
72	Shimura, C., et al., <i>Dendritic cells express hematopoietic prostaglandin D synthase and function as a source of prostaglandin D2 in the skin</i> . Am J Pathol, 2010. 176(1): p. 227-37.
73	Ziegler, A., et al., <i>Identification and characterization of equine blood plasmacytoid dendritic cells</i> . Dev Comp Immunol, 2016. 65: p. 352-357.
74	Hildner, K., et al., <i>Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity</i> . Science, 2008. 322(5904): p. 1097-100.
75	Lei, X., et al., <i>CD4(+) helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment</i> . Nat Commun, 2023. 14(1): p. 217.
76	Melief, S.M., et al., <i>Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature</i> . Cancer Immunol Res, 2017. 5(2): p. 170-179.
77	Barut, G.T., et al., <i>Single-cell transcriptomics reveals striking heterogeneity and functional organization of dendritic and monocytic cells in the bovine mesenteric lymph node</i> . Front Immunol, 2022. 13: p. 1099357.
78	Choi, B.K., et al., <i>RELT negatively regulates the early phase of the T-cell response in mice</i> . Eur J Immunol, 2018. 48(10): p. 1739-1749.
79	Fromm, P.D., et al., <i>Distinguishing human peripheral blood CD16(+) myeloid cells based on phenotypic characteristics</i> . J Leukoc Biol, 2020. 107(2): p. 323-339.
80	Pullikuth, A.K., et al., <i>Bulk and Single-Cell Profiling of Breast Tumors Identifies TREM-1 as a Dominant Immune Suppressive Marker Associated With Poor Outcomes</i> . Front Oncol, 2021. 11: p. 734959.
81	Brown, C.C., et al., <i>Transcriptional Basis of Mouse and Human Dendritic Cell Heterogeneity</i> . Cell, 2019. 179(4): p. 846-863.e24.
82	Schott, J., et al., <i>Translational regulation of specific mRNAs controls feedback inhibition and survival during macrophage activation</i> . PLoS Genet, 2014. 10(6): p. e1004368.
83	Xue, D., et al., <i>Transcriptome landscape of myeloid cells in human skin reveals diversity, rare populations and putative DC progenitors</i> . J Dermatol Sci, 2020. 97(1): p. 41-49.
84	Heger, L., et al., <i>CLEC10A Is a Specific Marker for Human CD1c(+) Dendritic Cells and Enhances Their Toll-Like Receptor 7/8-Induced Cytokine Secretion</i> . Front Immunol, 2018. 9: p. 744.
85	Takano, H., et al., <i>Involvement of CD44 in mast cell proliferation during terminal differentiation</i> . Lab Invest, 2009. 89(4): p. 446-55.
86	Draber, P., et al., <i>Signal transduction and chemotaxis in mast cells</i> . Eur J Pharmacol, 2016. 778: p. 11-23.
87	Woidacki, K., et al., <i>Mast cells rescue implantation defects caused by c-kit deficiency</i> . Cell Death Dis, 2013. 4(1): p. e462.
88	Collison, A., et al., <i>Tumor necrosis factor-related apoptosis-inducing ligand regulates hallmark features of airways remodeling in allergic airways disease</i> . Am J Respir Cell Mol Biol, 2014. 51(1): p. 86-93.
89	Andrade, F.E.C., et al., <i>Galectin-3: role in ocular allergy and potential as a predictive biomarker</i> . Br J Ophthalmol, 2018. 102(7): p. 1003-1010.
90	Ushio, H., et al., <i>Crucial role for autophagy in degranulation of mast cells</i> . J Allergy Clin Immunol, 2011. 127(5): p. 1267-76.e6.
91	Caughey, G.H., <i>Mast cell tryptases and chymases in inflammation and host defense</i> . Immunol Rev, 2007. 217: p. 141-54.
92	Pereira, H.A., et al., <i>CAP37, a human neutrophil-derived chemotactic factor with monocyte specific activity</i> . J Clin Invest, 1990. 85(5): p. 1468-76.
93	Jayapal, M., et al., <i>Genome-wide gene expression profiling of human mast cells stimulated by IgE or FcepsilonRI aggregation reveals a complex network of genes involved in inflammatory responses</i> . BMC Genomics, 2006. 7: p. 210.

Reference number	Reference
94	Di Nardo, A., et al., <i>Mast cell tolerance in the skin microenvironment to commensal bacteria is controlled by fibroblasts</i> . Cell Rep, 2023. 42(5): p. 112453.
95	Rouers, A., et al., <i>CD27(hi)CD38(hi) plasmablasts are activated B cells of mixed origin with distinct function</i> . iScience, 2021. 24(5): p. 102482.
96	Le, T.A., et al., <i>Efficient CRISPR-Cas9-mediated mutagenesis in primary human B cells for identifying plasma cell regulators</i> . Mol Ther Nucleic Acids, 2022. 30: p. 621-632.
97	Patterson, D.G., et al., <i>An IRF4-MYC-mTORC1 Integrated Pathway Controls Cell Growth and the Proliferative Capacity of Activated B Cells during B Cell Differentiation In Vivo</i> . J Immunol, 2021. 207(7): p. 1798-1811.
98	Liu, B. and Z. Li, <i>Endoplasmic reticulum HSP90b1 (gp96, grp94) optimizes B-cell function via chaperoning integrin and TLR but not immunoglobulin</i> . Blood, 2008. 112(4): p. 1223-30.
99	Morgan, D. and V. Tergaonkar, <i>Unraveling B cell trajectories at single cell resolution</i> . Trends Immunol, 2022. 43(3): p. 210-229.
100	Preisendörfer, S., et al., <i>FK506-Binding Protein 11 Is a Novel Plasma Cell-Specific Antibody Folding Catalyst with Increased Expression in Idiopathic Pulmonary Fibrosis</i> . Cells, 2022. 11(8).
101	Hu, J., et al., <i>Lysophosphatidic acid receptor 5 inhibits B cell antigen receptor signaling and antibody response</i> . J Immunol, 2014. 193(1): p. 85-95.
102	van der Vuurst de Vries, A.R., et al., <i>Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is differentially expressed during human B cell differentiation and inhibits B cell receptor-mediated signaling</i> . Eur J Immunol, 1999. 29(10): p. 3160-7.
103	Okada, S.S., et al., <i>Myeloperoxidase in human peripheral blood lymphocytes: Production and subcellular localization</i> . Cell Immunol, 2016. 300: p. 18-25.
104	Chertov, O., et al., <i>Leukocyte granule proteins mobilize innate host defenses and adaptive immune responses</i> . Immunol Rev, 2000. 177: p. 68-78.
105	Murphy, T.L., R. Tussiwand, and K.M. Murphy, <i>Specificity through cooperation: BATF-IRF interactions control immune-regulatory networks</i> . Nat Rev Immunol, 2013. 13(7): p. 499-509.
106	Gagro, A., et al., <i>Type I cytokine profiles of human naïve and memory B lymphocytes: a potential for memory cells to impact polarization</i> . Immunology, 2006. 118(1): p. 66-77.
107	Jasso, G.J., et al., <i>Colon stroma mediates an inflammation-driven fibroblastic response controlling matrix remodeling and healing</i> . PLoS Biol, 2022. 20(1): p. e3001532.
108	Schupp, J.C., et al., <i>Integrated Single-Cell Atlas of Endothelial Cells of the Human Lung</i> . Circulation, 2021. 144(4): p. 286-302.
109	Geldhof, V., et al., <i>Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast</i> . Nat Commun, 2022. 13(1): p. 5511.
110	Goveia, J., et al., <i>An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates</i> . Cancer Cell, 2020. 37(1): p. 21-36.e13.
111	Li, Q., et al., <i>An IGFBP7hi endothelial cell subset drives T cell extravasation in psoriasis via endothelial glycocalyx degradation</i> . J Clin Invest, 2023. 133(9).
112	Arora, L. and D. Pal, <i>Remodeling of Stromal Cells and Immune Landscape in Microenvironment During Tumor Progression</i> . Front Oncol, 2021. 11: p. 596798.
113	Lebrin, F., et al., <i>Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction</i> . Embo j, 2004. 23(20): p. 4018-28.
114	Wang, R., et al., <i>Integrative Analysis of Bulk RNA-Seq and Single-Cell RNA-Seq Unveils the Characteristics of the Immune Microenvironment and Prognosis Signature in Prostate Cancer</i> . J Oncol, 2022. 2022: p. 6768139.
115	Boraas, L.C. and T. Ahsan, <i>Lack of vimentin impairs endothelial differentiation of embryonic stem cells</i> . Sci Rep, 2016. 6: p. 30814.
116	Förster, R., A.C. Davalos-Misslitz, and A. Rot, <i>CCR7 and its ligands: balancing immunity and tolerance</i> . Nat Rev Immunol, 2008. 8(5): p. 362-71.
117	Amsellem, V., et al., <i>ICAM-2 regulates vascular permeability and N-cadherin localization through ezrin-radixin-moesin (ERM) proteins and Rac-1 signalling</i> . Cell Commun Signal, 2014. 12: p. 12.

References of Supplemental Table 5 Continued

Reference number	Reference
118	Zhang, Q., et al., <i>Insulin-like growth factor binding protein-3 inhibits monocyte adhesion to retinal endothelial cells in high glucose conditions</i> . Mol Vis, 2013. 19: p. 796-803.
119	Swaminathan, B., et al., <i>Endothelial Notch signaling directly regulates the small GTPase RND1 to facilitate Notch suppression of endothelial migration</i> . Sci Rep, 2022. 12(1): p. 1655.
120	Cui, X.B., et al., <i>RGC-32 (Response Gene to Complement 32) Deficiency Protects Endothelial Cells From Inflammation and Attenuates Atherosclerosis</i> . Arterioscler Thromb Vasc Biol, 2018. 38(4): p. e36-e47.
121	Rho, S.S., et al., <i>Clec14a is specifically expressed in endothelial cells and mediates cell to cell adhesion</i> . Biochem Biophys Res Commun, 2011. 404(1): p. 103-8.
122	Barreiro, O., et al., <i>Endothelial tetraspanin microdomains regulate leukocyte firm adhesion during extravasation</i> . Blood, 2005. 105(7): p. 2852-61.
123	Shafi, A.M., et al., <i>Brain endothelial cells exposure to malaria parasites links type I interferon signalling to antigen presentation, immunoproteasome activation, endothelium disruption, and cellular metabolism</i> . Front Immunol, 2023. 14: p. 1149107.
124	Pilling, D., et al., <i>TNF-α-stimulated fibroblasts secrete lumican to promote fibrocyte differentiation</i> . Proc Natl Acad Sci U S A, 2015. 112(38): p. 11929-34.
125	Caetano, A.J., et al., <i>Defining human mesenchymal and epithelial heterogeneity in response to oral inflammatory disease</i> . Elife, 2021. 10.
126	Ascensión, A.M., et al., <i>Human Dermal Fibroblast Subpopulations Are Conserved across Single-Cell RNA Sequencing Studies</i> . J Invest Dermatol, 2021. 141(7): p. 1735-1744.e35.
127	Caetano, A.J., et al., <i>Spatially resolved transcriptomics reveals pro-inflammatory fibroblast involved in lymphocyte recruitment through CXCL8 and CXCL10</i> . Elife, 2023. 12.
128	Huang, Y., et al., <i>Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy</i> . Proc Natl Acad Sci U S A, 2012. 109(43): p. 17561-6.
129	Lu, J., et al., <i>CXCL14 as an emerging immune and inflammatory modulator</i> . J Inflamm (Lond), 2016. 13: p. 1.
130	Janson, D.G., et al., <i>Different gene expression patterns in human papillary and reticular fibroblasts</i> . J Invest Dermatol, 2012. 132(11): p. 2565-72.
131	Yasuoka, H., Y. Yamaguchi, and C.A. Feghali-Bostwick, <i>The pro-fibrotic factor IGFBP-5 induces lung fibroblast and mononuclear cell migration</i> . Am J Respir Cell Mol Biol, 2009. 41(2): p. 179-88.
132	Ma, C., et al., <i>Pan-cancer spatially resolved single-cell analysis reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment</i> . Mol Cancer, 2023. 22(1): p. 170.
133	He, H., et al., <i>Single-cell transcriptome analysis of human skin identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic dermatitis</i> . J Allergy Clin Immunol, 2020. 145(6): p. 1615-1628.
134	Ogata, Y., et al., <i>SASP-induced macrophage dysfunction may contribute to accelerated senescent fibroblast accumulation in the dermis</i> . Exp Dermatol, 2021. 30(1): p. 84-91.
135	Kim, H.J. and C. Neophytou, <i>Natural anti-inflammatory compounds for the management and adjuvant therapy of inflammatory bowel disease and its drug delivery system</i> . Arch Pharm Res, 2009. 32(7): p. 997-1004.
136	Farsam, V., et al., <i>Senescent fibroblast-derived Chemerin promotes squamous cell carcinoma migration</i> . Oncotarget, 2016. 7(50): p. 83554-83569.
137	Ezure, T., M. Sugahara, and S. Amano, <i>Senescent dermal fibroblasts negatively influence fibroblast extracellular matrix-related gene expression partly via secretion of complement factor D</i> . Biofactors, 2019. 45(4): p. 556-562.
138	Hanley, C.J., et al., <i>Single-cell analysis reveals prognostic fibroblast subpopulations linked to molecular and immunological subtypes of lung cancer</i> . Nat Commun, 2023. 14(1): p. 387.
139	Qiu, L.Q., et al., <i>Tristetraprolin (TTP) coordinately regulates primary and secondary cellular responses to proinflammatory stimuli</i> . J Leukoc Biol, 2015. 97(4): p. 723-36.

References

1. Saxena M, van der Burg SH, Melief CJM, et al. Therapeutic cancer vaccines. *Nat Rev Cancer* 2021;21(6):360-78. doi: 10.1038/s41568-021-00346-0 [published Online First: 2021/04/29]
2. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. *Science* 2015;348(6230):62-8. doi: 10.1126/science.aaa4967 [published Online First: 2015/04/04]
3. Zappasodi R, Merghoub T, Wolchok JD. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. *Cancer Cell* 2018;33(4):581-98. doi: 10.1016/j.ccell.2018.03.005 [published Online First: 2018/04/11]
4. Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. *Nat Med* 2018;24(5):541-50. doi: 10.1038/s41591-018-0014-x [published Online First: 2018/04/25]
5. Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. *Nat Rev Cancer* 2020;20(11):662-80. doi: 10.1038/s41568-020-0285-7 [published Online First: 2020/08/06]
6. Helmink BA, Reddy SM, Gao J, et al. B cells and tertiary lymphoid structures promote immunotherapy response. *Nature* 2020;577(7791):549-55. doi: 10.1038/s41586-019-1922-8 [published Online First: 2020/01/17]
7. Wang XQ, Danenberg E, Huang CS, et al. Spatial predictors of immunotherapy response in triple-negative breast cancer. *Nature* 2023;621(7980):868-76. doi: 10.1038/s41586-023-06498-3 [published Online First: 2023/09/07]
8. Bill R, Wirapati P, Messemaker M, et al. CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers. *Science* 2023;381(6657):515-24. doi: 10.1126/science.ade2292 [published Online First: 2023/08/03]
9. Abdulrahman Z, Santegoets SJ, Sturm G, et al. Tumor-specific T cells support chemokine-driven spatial organization of intratumoral immune microaggregates needed for long survival. *Journal for ImmunoTherapy of Cancer* 2022;10(2):e004346. doi: 10.1136/jitc-2021-004346
10. Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. *N Engl J Med* 2009;361(19):1838-47. doi: 10.1056/NEJMoa0810097 [published Online First: 2009/11/06]
11. van Poelgeest MI, Welters MJ, Vermeij R, et al. Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response. *Clin Cancer Res* 2016;22(10):2342-50. doi: 10.1158/1078-0432.Ccr-15-2594 [published Online First: 2016/01/28]
12. Lee J, Nicosia M, Hong ES, et al. Sex-Biased T-cell Exhaustion Drives Differential Immune Responses in Glioblastoma. *Cancer Discov* 2023;13(9):2090-105. doi: 10.1158/2159-8290.Cd-22-0869 [published Online First: 2023/06/28]
13. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β -catenin signalling prevents anti-tumour immunity. *Nature* 2015;523(7559):231-5. doi: 10.1038/nature14404 [published Online First: 2015/05/15]
14. Peng W, Chen JQ, Liu C, et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. *Cancer Discov* 2016;6(2):202-16. doi: 10.1158/2159-8290.Cd-15-0283 [published Online First: 2015/12/10]
15. Liu C, Peng W, Xu C, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. *Clin Cancer Res* 2013;19(2):393-403. doi: 10.1158/1078-0432.Ccr-12-1626 [published Online First: 2012/12/04]
16. Santegoets SJ, van Ham VJ, Ehsan I, et al. The Anatomical Location Shapes the Immune Infiltrate in Tumors of Same Etiology and Affects Survival. *Clin Cancer Res* 2019;25(1):240-52. doi: 10.1158/1078-0432.Ccr-18-1749 [published Online First: 2018/09/19]
17. Welters MJ, Kenter GG, de Vos van Steenwijk PJ, et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. *Proc Natl Acad Sci U S A* 2010;107(26):11895-9. doi: 10.1073/pnas.1006500107 [published Online First: 2010/06/16]

18. Abdulrahman Z, de Miranda N, van Esch EMG, et al. Pre-existing inflammatory immune microenvironment predicts the clinical response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 vaccination. *Journal for ImmunoTherapy of Cancer* 2020;8(1):e000563. doi: 10.1136/jitc-2020-000563
19. He S, Bhatt R, Brown C, et al. High-plex imaging of RNA and proteins at subcellular resolution in fixed tissue by spatial molecular imaging. *Nat Biotechnol* 2022;40(12):1794-806. doi: 10.1038/s41587-022-01483-z [published Online First: 2022/10/07]
20. Hornburg M, Desbois M, Lu S, et al. Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. *Cancer Cell* 2021;39(7):928-44.e6. doi: 10.1016/j.ccell.2021.04.004 [published Online First: 2021/05/08]
21. Zilionis R, Engblom C, Pfirschke C, et al. Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species. *Immunity* 2019;50(5):1317-34. e10. doi: 10.1016/j.immuni.2019.03.009 [published Online First: 2019/04/14]
22. Zhang Y, Chen H, Mo H, et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. *Cancer Cell* 2021;39(12):1578-93.e8. doi: 10.1016/j.ccell.2021.09.010 [published Online First: 2021/10/16]
23. Maier B, Leader AM, Chen ST, et al. A conserved dendritic-cell regulatory program limits antitumour immunity. *Nature* 2020;580(7802):257-62. doi: 10.1038/s41586-020-2134-y [published Online First: 2020/04/10]
24. Wang Y, Zhao J, Xu H, et al. A systematic evaluation of computational methods for cell segmentation. *Brief Bioinform* 2024;25(5):e407. doi: 10.1093/bib/bbae407 [published Online First: 2024/08/18]
25. Danaher P, Zhao E, Yang Z, et al. Insitutype: likelihood-based cell typing for single cell spatial transcriptomics. *bioRxiv* 2022:2022.10.19.512902.
26. Laue J, Berens P, Kobak D. Analytic Pearson residuals for normalization of single-cell RNA-seq UMI data. *Genome Biol* 2021;22(1):258. doi: 10.1186/s13059-021-02451-7 [published Online First: 2021/09/08]
27. Butler A, Hoffman P, Smibert P, et al. Integrating single-cell transcriptomic data across different conditions, technologies, and species. *Nat Biotechnol* 2018;36(5):411-20. doi: 10.1038/nbt.4096 [published Online First: 2018/04/03]
28. Vasconcelos AG, McGuire D, Simon N, et al. Differential Expression Analysis for Spatially Correlated Data. *bioRxiv* 2024:2024.08.02.606405.
29. Venables WN, Ripley B. Modern applied statistics with S. *Statistics and Computing* New York: Springer 2002
30. Lenth R. emmeans: Estimated marginal means, aka least-squares means. R package version 1.7.2, 2022.
31. Domínguez Conde C, Xu C, Jarvis LB, et al. Cross-tissue immune cell analysis reveals tissue-specific features in humans. *Science* 2022;376(6594):eabl5197. doi: 10.1126/science.abl5197 [published Online First: 2022/05/14]
32. Kong L, Pokatayev V, Lefkovich A, et al. The landscape of immune dysregulation in Crohn's disease revealed through single-cell transcriptomic profiling in the ileum and colon. *Immunity* 2023;56(2):444-58. e5. doi: 10.1016/j.immuni.2023.01.002 [published Online First: 2023/02/01]
33. Bassez A, Vos H, Van Dyck L, et al. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. *Nat Med* 2021;27(5):820-32. doi: 10.1038/s41591-021-01323-8 [published Online First: 2021/05/08]
34. Franken A, Bila M, Mechels A, et al. CD4(+) T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy. *Immunity* 2024;57(3):541-58.e7. doi: 10.1016/j.immuni.2024.02.007 [published Online First: 2024/03/06]
35. Kang J, Lee JH, Cha H, et al. Systematic dissection of tumor-normal single-cell ecosystems across a thousand tumors of 30 cancer types. *Nat Commun* 2024;15(1):4067. doi: 10.1038/s41467-024-48310-4 [published Online First: 2024/05/15]
36. Freedberg IM, Tomic-Canic M, Komine M, et al. Keratins and the keratinocyte activation cycle. *J Invest Dermatol* 2001;116(5):633-40. doi: 10.1046/j.1523-1747.2001.01327.x [published Online First: 2001/05/12]
37. Li Q, Shao S, Zhu Z, et al. An IGFBP7hi endothelial cell subset drives T cell extravasation in psoriasis via endothelial glycocalyx degradation. *J Clin Invest* 2023;133(9):e160451. doi: 10.1172/jci160451 [published Online First: 2023/03/15]

38. Islam SA, Ling MF, Leung J, et al. Identification of human CCR8 as a CCL18 receptor. *J Exp Med* 2013;210(10):1889-98. doi: 10.1084/jem.20130240 [published Online First: 2013/09/04]
39. de Nadaï P, Charbonnier AS, Chenivesse C, et al. Involvement of CCL18 in allergic asthma. *J Immunol* 2006;176(10):6286-93. doi: 10.4049/jimmunol.176.10.6286 [published Online First: 2006/05/04]
40. Chenivesse C, Chang Y, Azzaoui I, et al. Pulmonary CCL18 recruits human regulatory T cells. *J Immunol* 2012;189(1):128-37. doi: 10.4049/jimmunol.1003616 [published Online First: 2012/06/01]
41. Lu J, Chatterjee M, Schmid H, et al. CXCL14 as an emerging immune and inflammatory modulator. *J Inflamm (Lond)* 2016;13:1. doi: 10.1186/s12950-015-0109-9 [published Online First: 2016/01/07]
42. Augsten M, Hägglöf C, Olsson E, et al. CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. *Proc Natl Acad Sci U S A* 2009;106(9):3414-9. doi: 10.1073/pnas.0813144106 [published Online First: 2009/02/17]
43. Augsten M, Sjöberg E, Frings O, et al. Cancer-associated fibroblasts expressing CXCL14 rely upon NOS1-derived nitric oxide signaling for their tumor-supporting properties. *Cancer Res* 2014;74(11):2999-3010. doi: 10.1158/0008-5472.Can-13-2740 [published Online First: 2014/04/09]
44. Hara T, Tanegashima K. Pleiotropic functions of the CXC-type chemokine CXCL14 in mammals. *J Biochem* 2012;151(5):469-76. doi: 10.1093/jb/mvs030 [published Online First: 2012/03/23]
45. Pan Q, Liu R, Zhang X, et al. CXCL14 as a potential marker for immunotherapy response prediction in renal cell carcinoma. *Ther Adv Med Oncol* 2023;15:17588359231217966. doi: 10.1177/17588359231217966 [published Online First: 2023/12/28]
46. Kumar A, Mohamed E, Tong S, et al. CXCL14 Promotes a Robust Brain Tumor-Associated Immune Response in Glioma. *Clin Cancer Res* 2022;28(13):2898-910. doi: 10.1158/1078-0432.Ccr-21-2830 [published Online First: 2022/05/06]
47. Zeng W, Xiong L, Wu W, et al. CCL18 signaling from tumor-associated macrophages activates fibroblasts to adopt a chemoresistance-inducing phenotype. *Oncogene* 2023;42(3):224-37. doi: 10.1038/s41388-022-02540-2 [published Online First: 2022/11/24]
48. Lin L, Chen YS, Yao YD, et al. CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer. *Oncotarget* 2015;6(33):34758-73. doi: 10.18632/oncotarget.5325 [published Online First: 2015/09/30]
49. Fridman WH, Pagès F, Sautès-Fridman C, et al. The immune contexture in human tumours: impact on clinical outcome. *Nat Rev Cancer* 2012;12(4):298-306. doi: 10.1038/nrc3245 [published Online First: 2012/03/16]
50. Lin MJ, Svensson-Arvelund J, Lubitz GS, et al. Cancer vaccines: the next immunotherapy frontier. *Nat Cancer* 2022;3(8):911-26. doi: 10.1038/s43018-022-00418-6 [published Online First: 2022/08/24]
51. Kirkwood JM, Lee S, Moschos SJ, et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-macrophage colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. *Clin Cancer Res* 2009;15(4):1443-51. doi: 10.1158/1078-0432.Ccr-08-1231 [published Online First: 2009/02/21]
52. Melief CJM, Welters MJP, Vergote I, et al. Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. *Sci Transl Med* 2020;12(535) doi: 10.1126/scitranslmed.aaz8235 [published Online First: 2020/03/20]
53. Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. *Nature* 2023;618(7963):144-50. doi: 10.1038/s41586-023-06063-y [published Online First: 2023/05/11]
54. Borst J, Ahrends T, Bąbała N, et al. CD4(+) T cell help in cancer immunology and immunotherapy. *Nat Rev Immunol* 2018;18(10):635-47. doi: 10.1038/s41577-018-0044-0 [published Online First: 2018/07/31]
55. Espinosa-Carrasco G, Chiu E, Scrivo A, et al. Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. *Cancer Cell* 2024;42(7):1202-16.e8. doi: 10.1016/j.ccell.2024.05.025 [published Online First: 2024/06/22]
56. Luca BA, Steen CB, Matusiak M, et al. Atlas of clinically distinct cell states and ecosystems across human solid tumors. *Cell* 2021;184(21):5482-96.e28. doi: 10.1016/j.cell.2021.09.014 [published Online First: 2021/10/02]

57. Welters MJP, Ma W, Santegoets S, et al. Intratumoral HPV16-Specific T Cells Constitute a Type I-Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer. *Clin Cancer Res* 2018;24(3):634-47. doi: 10.1158/1078-0432.Ccr-17-2140 [published Online First: 2017/10/12]
58. Duurland CL, Santegoets SJ, Abdulrahman Z, et al. CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors. *Journal for ImmunoTherapy of Cancer* 2022;10(1):e003995. doi: 10.1136/jitc-2021-003995
59. Mathy NL, Scheuer W, Lanzendörfer M, et al. Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. *Immunology* 2000;100(1):63-9. doi: 10.1046/j.1365-2567.2000.00997.x [published Online First: 2000/05/16]
60. Kaser A, Dunzendorfer S, Offner FA, et al. A role for IL-16 in the cross-talk between dendritic cells and T cells. *J Immunol* 1999;163(6):3232-8. [published Online First: 1999/09/08]
61. Lynch EA, Heijens CA, Horst NF, et al. Cutting edge: IL-16/CD4 preferentially induces Th1 cell migration: requirement of CCR5. *J Immunol* 2003;171(10):4965-8. doi: 10.4049/jimmunol.171.10.4965 [published Online First: 2003/11/11]
62. Allen F, Bobanga ID, Rauhe P, et al. CCL3 augments tumor rejection and enhances CD8(+) T cell infiltration through NK and CD103(+) dendritic cell recruitment via IFN γ . *Oncoimmunology* 2018;7(3):e1393598. doi: 10.1080/2162402x.2017.1393598 [published Online First: 2018/02/06]
63. Galeano Niño JL, Pigeon SV, Tay SS, et al. Cytotoxic T cells swarm by homotypic chemokine signalling. *Elife* 2020;9:e56554.
64. van Elsas MJ, Middelburg J, Labrie C, et al. Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. *Cancer Cell* 2024;42(6):1032-50.e10. doi: 10.1016/j.ccell.2024.04.011 [published Online First: 2024/05/18]
65. Mami-Chouaib F, Blanc C, Corgnac S, et al. Resident memory T cells, critical components in tumor immunology. *J Immunother Cancer* 2018;6(1):87. doi: 10.1186/s40425-018-0399-6 [published Online First: 2018/09/06]
66. Kodelja V, Müller C, Politz O, et al. Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. *J Immunol* 1998;160(3):1411-8. [published Online First: 1998/05/07]
67. Korbecki J, Olbromski M, Dzięciel P. CCL18 in the progression of cancer. *International Journal of Molecular Sciences* 2020;21(21):7955.
68. Sui X, Chen C, Zhou X, et al. Integrative analysis of bulk and single-cell gene expression profiles to identify tumor-associated macrophage-derived CCL18 as a therapeutic target of esophageal squamous cell carcinoma. *J Exp Clin Cancer Res* 2023;42(1):51. doi: 10.1186/s13046-023-02612-5 [published Online First: 2023/03/01]